US20090175953A1 - Nanodispersions - Google Patents
Nanodispersions Download PDFInfo
- Publication number
- US20090175953A1 US20090175953A1 US12/309,306 US30930607A US2009175953A1 US 20090175953 A1 US20090175953 A1 US 20090175953A1 US 30930607 A US30930607 A US 30930607A US 2009175953 A1 US2009175953 A1 US 2009175953A1
- Authority
- US
- United States
- Prior art keywords
- soluble
- solvent
- water
- payload
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to dried compositions which form so-called ‘nano dispersions’ when placed in water or other solvents and deliver a material which is not normally soluble in water or said other solvent.
- An emulsion of the aqueous and non-aqueous solutions is prepared and then dried, such as by freeze or spray drying, to form a material which is believed to comprise a nano-scale dispersion of an insoluble ‘payload’ material in a soluble matrix formed from the ‘carrier’ material.
- a similar approach can be used to provide oil-insoluble payload materials which are rapidly dispersible in oils and other non-aqueous solvents by forming a nano-dispersion of these payload materials in an oil-soluble carrier.
- the matrix of carrier material dissolves releasing the nano-disperse payload material. This forms a solution-like ‘nano-dispersion’ of the supposedly water-insoluble payload material.
- the payload and the carrier are referred to in the present specification as ‘contra-soluble’ where one is soluble in water (or aqueous solution) and the other is effectively insoluble in water (or aqueous solution) but is soluble in some at least partially non-aqueous solvent.
- WO 2005/011636 discloses a non-emulsion based spray drying process for forming ‘solid amorphous dispersions’ of drugs in polymers.
- a polymer and a low-solubility drug are dissolved in a solvent and spray-dried to form dispersions in which the drug is mostly present in an amorphous form rather than in a crystalline form.
- the product form is believed to be a solid solution. That is, both the drug and the polymer are present in a single, undifferentiated phase. Solid solutions are believed to form only at particular component ratios and there is therefore little formulation flexibility with these systems.
- the present invention provides a process for making contra-soluble nano-dispersions of at most sparingly-soluble materials in a soluble carrier material comprising the steps of:
- insoluble as applied to payload means that its solubility in the target environment is less than 10 g/L at ambient temperature. For water-insoluble payload materials this would be a solubility of less than 10 g/L in water.
- nanoparticles are particles which are smaller than one micron and larger than 1 nm.
- Payload materials preferably have a normal solubility (from a solid or powder form) at ambient temperature (20 Celsius) in their target environment of less than 5 g/L preferably of less than 1 g/L, especially preferably less than 120 mg/L, even more preferably less than 15 mg/L and most preferably less than 5 mg/L.
- the carrier material (b) and the payload (c) are not present in the same phase after drying.
- the payload is believed to be present as a nanoparticle phase dispersed through a continuous phase of the carrier material.
- the preferred method of particle sizing for the dispersed products of the present invention employs a dynamic light scattering instrument (“Nano S”, manufactured by Malvern Instruments UK). Specifically, the Malvern Instruments Nano S uses a red (633 nm) 4 mW Helium-Neon laser to illuminate a standard optical quality UV curvette containing a suspension of material.
- the particle sizes quoted in this application are those obtained with that apparatus using the standard protocol.
- Particle sizes in solid products are the particle sizes inferred from the measurement of the particle size obtained by solution of the solid form and subsequent measurement of the particle size.
- ambient temperature means 20 degrees Celsius and all percentages are percentages by weight unless otherwise specified.
- drying means the removal of such aqueous and non-aqueous solvents as are present.
- the drying process is conducted above ambient temperature.
- the drying process is a spray-drying process.
- Less preferable alternatives to spray-drying include freeze-drying which is conducted below ambient temperature.
- the feedstock to the dryer is essentially free of solids (when at ambient temperature). Where solids are present in the dryer feedstock these should not comprise more than 10%, preferably not more that 5% of the feedstock.
- a non-aqueous solvent is employed in which both the payload and the carrier are soluble.
- This solvent can comprise a single solvent species or a mixture of solvent species.
- Preferred solvents are polar, protic or aprotic solvents.
- Generally preferred solvents have a dipole moment greater than 1 and a dielectric constant greater than 4.5.
- Particularly preferred solvents are selected from the group consisting of haloforms (preferably dichloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and other water miscible species comprising a hetroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide).
- haloforms preferably dichloromethane, chloroform
- lower (C1-C10) alcohols preferably methanol, ethanol, isopropanol, isobutanol
- organic acids preferably formic acid, acetic acid
- a mixture of miscible solvents are used in which mixture both the payload and the matrix are soluble, and wherein at least one of the solvents is an aqueous solvent and at least another solvent is a non-aqueous solvent.
- the non-aqueous solvent is selected from one or more of the polar protic or polar aprotic solvents listed above.
- a solvent which comprises only an aqueous phase provided it can dissolve both an oil-insoluble payload material and a carrier which is also oil-soluble. This method is used for the production of materials which comprise a nano-dispersion of a water-soluble material in an oil-soluble carrier.
- Solvent systems employed in the present invention are not limited to binary mixtures, but can include three or more components. Additional water-immiscible solvents can be present provided that they are miscible in the solvent mixture as a whole. These additional water-immiscible solvents need not fulfill the conditions as regards either dipole moment and/or dielectric constant as given above and include, for example, linear hydrocarbons (preferably hexane), cyclic hydrocarbons (preferably cyclohexane), halocarbons (preferably carbon tetrachloride, methylene chloride) and ethers (preferably diethyl ether).
- linear hydrocarbons preferably hexane
- cyclic hydrocarbons preferably cyclohexane
- halocarbons preferably carbon tetrachloride, methylene chloride
- ethers preferably diethyl ether
- the ‘carrier’ and the ‘payload’ material are both soluble in a single phase (which can be a single solvent or a mixture of solvents) the use of an emulsion in the drying process is not altogether excluded as other materials may be present which are not miscible provided that there exists at least one single phase which comprises both the carrier and the payload.
- the solvents present are removed simultaneously, rather than sequentially, in a single drying step.
- the carrier material is rapidly soluble in water as well as in the solvent or solvent mixtures used to form the feed for the drying step.
- the carrier will quickly dissolve and release the payload material in nano-disperse form.
- the carrier will deliver a material that is water-soluble into a non-aqueous environment
- the carrier should preferably be rapidly soluble in that environment.
- oil is used to indicate a non-aqueous environment.
- typical particle sizes for the dispersed form of the payload material after delivery may be determined by use, for example, of a MalvernTM ‘Nano-S’ apparatus. Results generally fall into the range from 500-2 nm (expressed as a diameter) and this particle size range is preferred, with 300-4 nm being particularly preferred. For comparative purposes, the range is analogous to the size of a virus particle (which typically range from 450-20 nm). The size distribution may show more than one peak.
- the “solutions” obtained are not true solutions comprising a material dispersed on a molecular scale but are nano-scale dispersions in which the ‘soluble’ material retains some organized structure but on such a small scale that it has many of the properties of a true solution.
- dispersing a water-insoluble bleach from products of the present invention results in the bleach being more finely dispersed and reduces the spot damage seen when larger water-insoluble particles of the bleach contact a fabric.
- compositions of the invention are not solid solutions, but comprise a nano-scale, phase-separated mixture.
- the compositions of the present invention can be varied as regards the ratios of the carrier and the payload, again indicating that they are not solid solutions which are generally only formed at specific component ratios.
- the invention uses a carrier and a payload which are “contra-soluble” in water and a non-aqueous solvent.
- a carrier and a payload which are “contra-soluble” in water and a non-aqueous solvent.
- a process for preparing a form of an oil-insoluble material which is dispersible in oil using a mixed aqueous/non-aqueous solvent system and,
- a process for preparing a form of an oil insoluble material which is dispersible in oil using a wholly aqueous solvent system is a process for preparing a form of an oil insoluble material which is dispersible in oil using a wholly aqueous solvent system.
- Types I and II are the preferred processes. It will be noted that in both I and II water soluble carrier materials and water insoluble payload materials are used. Preferred payload and carrier materials for processes of types I and II are described if further detail below.
- water-insoluble ‘payload’ materials are given below. These are given as examples only and are not intended to limit the applicability of the present invention. Those skilled in the art will however realize that the materials of the present invention will have utility in other areas not specifically exemplified herein.
- Water insoluble (hydrophobic) materials that are released from the products obtained by the process of the present invention at the time of use and can be utilized in the process of the present invention preferably include:—
- Whether a type I or a type II process is used will depend on whether the water-insoluble payload material is soluble in a wholly non-aqueous solvent or a water-containing mixture of solvents. If the payload material is only soluble in a mixture containing water then the type I process (mixed aqueous/non-aqueous solvents) must be used.
- Suitable carrier materials include the preferred water-soluble polymers, preferred water-soluble surfactants and preferred water-soluble inorganic materials as described in further detail below. These lists are not exhaustive as other water-soluble materials, for example citric acid, can be used.
- Carrier materials for processes of types I and II are water soluble as well as being soluble in at least one of the aqueous/non-aqueous solvent system of type I processes or the anhydrous solvent system of type II processes. As these materials are all water-soluble they will generally be soluble in the solvent combinations of the type I process.
- Suitable water-soluble polymeric carrier materials include:
- the polymeric material when it is a copolymer it may be a statistical copolymer (heretofore also known as a random copolymer), a block copolymer, a graft copolymer or a hyperbranched copolymer. Comonomers other than those listed above may also be included in addition to those listed if their presence does not destroy the water soluble or water dispersible nature of the resulting polymeric material.
- suitable and preferred homopolymers include poly-vinylalcohol, poly-acrylic acid, poly-methacrylic acid, poly-acrylamides (such as poly-N-isopropylacrylamide), poly-methacrylamide; poly-acrylamines, poly-methyl-acrylamines, (such as polydimethylaminoethylmethacrylate and poly-N-morpholinoethylmethacrylate), polyvinylpyrrolidone, poly-styrenesulphonate, polyvinylimidazole, polyvinylpyridine, poly-2-ethyl-oxazoline poly-ethyleneimine and ethoxylated derivatives thereof.
- Polyethylene glycol PEG
- Polyvinyl alcohol PVA
- polyvinylpyrrolidone PVP
- HPMC hydroxypropyl celluose
- HPMC hydroxypropyl methyl-cellulose
- the surfactant may be non-ionic, anionic, cationic, amphoteric or zwitterionic.
- non-ionic surfactants include ethoxylated triglycerides; fatty alcohol ethoxylates; alkylphenol ethoxylates; fatty acid ethoxylates; fatty amide ethoxylates; fatty amine ethoxylates; sorbitan alkanoates; ethylated sorbitan alkanoates; alkyl ethoxylates; PluronicsTM; alkyl polyglucosides; stearol ethoxylates; alkyl polyglycosides.
- anionic surfactants include alkylether sulfates; alkylether carboxylates; alkylbenzene sulfonates; alkylether phosphates; dialkyl sulfosuccinates; alkyl sulfonates; soaps; alkyl sulfates; alkyl carboxylates; alkyl phosphates; paraffin sulfonates; secondary n-alkane sulfonates; alpha-olefin sulfonates; isethionate sulfonates.
- Suitable cationic surfactants include fatty amine salts; fatty diamine salts; quaternary ammonium compounds; phosphonium surfactants; sulfonium surfactants; sulfonxonium surfactants.
- Suitable zwitterionic surfactants include N-alkyl derivatives of amino acids (such as glycine, betaine, aminopropionic acid); imidazoline surfactants; amine oxides; amidobetaines.
- Mixtures of surfactants may be used.
- Alkoxylated nonionic's (especially the PEG/PPG eg PluronicTM materials and/or the PEG/alcohol nonionics and/or aromatic nonionics, including phenol-ethoxylates (especially TritonTM materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the SpanTM and TweenTM types) and cationics (especially cetyltrimethylammonium bromide—CTAB) are particularly preferred as surfactant carrier materials.
- PEG/PPG eg PluronicTM materials and/or the PEG/alcohol nonionics and/or aromatic nonionics including phenol-ethoxylates (especially TritonTM materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the SpanTM and TweenTM types) and cationic
- the carrier material can also be a water-soluble inorganic material which is neither a surfactant not a polymer.
- Simple organic salts have been found suitable, particularly in admixture with polymeric and/or surfactant carrier materials as described above. Suitable salts include carbonate, bicarbonates, halides, sulphates, nitrates and acetates, particularly soluble salts of sodium, potassium and magnesium.
- Preferred materials include, sodium carbonate, sodium bicarbonate and sodium sulphate. These materials have the advantage that they are cheap and physiologically acceptable. They are also relatively inert as well as compatible with many materials found in household and pharmaceutical products.
- preferred mixtures include combinations of inorganic salts and surfactants and, in particular, mixtures of polymers and surfactants.
- Particularly preferred mixtures include combinations of surfactants and polymers which include at least one of:
- the level of surfactant carrier is such that at least 50% of the total carrier is surfactant. Mixtures having a majority of surfactant present over the other carriers exhibit enhanced payload effects.
- Both processes of types I and II use a non-aqueous solvent (or a mixture of said solvents).
- Particularly preferred solvents are selected from the group consisting of haloforms (preferably di-chloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and other water miscible species comprising hetroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide). Mixtures of the aforementioned may also be employed.
- haloforms preferably di-chloromethane, chloroform
- lower (C1-C10) alcohols preferably methanol, ethanol, isopropanol, isobutanol
- Preferred solvents include dichloromethane, chloroform, ethanol, acetone and dimethyl sulphoxide.
- Preferred non-aqueous solvents have a boiling point of less than 150 Celsius and, more preferably, have a boiling point of less than 100 Celsius, so as to facilitate drying, particularly spray-drying under practical conditions and without use of specialised equipment.
- they are non-flammable, or have a flash point above the temperatures encountered in the method of the invention.
- Type I Nano-Dispersible Forms of a Water-Insoluble Material Prepared Using a Mixed Solvent System
- This aspect of the invention provides a process for making a nano-dispersion of a water-in soluble material in a water-soluble carrier material comprising the steps of:
- the preferred aqueous solvent is water. Electrolyte solutions can also be used as the aqueous solvent.
- Type II Nano-Dispersible (in Water) Forms of a Water-Insoluble Material Using a Single Solvent System
- This aspect of the invention provides a process for making water-soluble nano-dispersions of at most sparingly water-soluble materials in a water-soluble carrier material comprising the steps of:
- Suitable carrier materials include the preferred water-soluble polymers and preferred water-soluble surfactants as mentioned above which are also soluble in the anhydrous non-aqueous solvent (or solvent mixture)
- Particularly preferred carrier materials for use in process type II are:
- Particularly preferred solvents are haloforms for use in process type II (preferably di-chloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and species comprising a hetroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide). Mixtures of the aforementioned may also be employed.
- C1-C10 alcohols preferably methanol, ethanol, isopropanol, isobutanol
- organic acids preferably formic acid, acetic acid
- amides preferably formamide, N,
- the presence of some low level of water in the non-aqueous solvent is not excluded, as a cheaper technical grade of the solvent may be used rather than a more expensive analytical grade.
- the level of water is below 1%.
- non-aqueous solvents Particular examples of non-aqueous solvents, payload materials soluble in the solvent and carrier materials also soluble in the solvent are provided in Table 2 below.
- Some materials exhibit a low solubility in both aqueous and non-aqueous solvents exhibit a low solubility in both aqueous and non-aqueous solvents (examples are Homoeriodictyol and divanillin), both of which are insoluble in water, ethanol and poly-propylene glycol. However these both materials are soluble in DMSO.
- a carrier which is also soluble in both DMSO and one of water, ethanol and PPG (for example PVP/HPC) it is possible to obtain a nano-disperse form of either payload material in the carrier, which can be “dissolved” in water, ethanol or PPG.
- Spray drying the most preferred method of drying, is well known to those versed in the art. In the case of the present invention some care must be taken due to the presence of a volatile non-aqueous solvent in the feedstock being dried.
- an inert gas for example nitrogen, can be employed as the drying medium in a so-called closed spray-drying system. The solvent can be recovered and re-used.
- the drying temperature should be at or above 100 Celsius, preferably above 120 Celsius and most preferably above 140 Celsius. Elevated drying temperatures have been found to give smaller particles in the re-dissolved nano-disperse material.
- an optional co-surfactant may be employed in the composition prior to the drying step.
- a relatively small quantity of a volatile cosurfactant reduced the particle diameter of the material produced. This can have a significant impact on particle volume. For example, reduction from 297 nm to 252 nm corresponds to a particle size reduction of approximately 40%.
- the addition of a small quantity of co-surfactant offers a simple and inexpensive method for reducing the particle size of materials according to the present invention without changing the final product formulation.
- Preferred co-surfactants are short chain alcohols or amine with a boiling point of ⁇ 220° C.
- Preferred co-surfactants are linear alcohols.
- Preferred co-surfactants are primary alcohols and amines. Particularly preferred co-surfactants are selected from the group consisting of the 3-6 carbon alcohols.
- Suitable alcohol co-surfactants include n-propanol, n-butanol, n-pentanol, n-hexanol, hexylamine and mixtures thereof.
- the co-surfactant is present in a quantity (by volume) less than the solvent preferably the volume ratio between the solvent and the co-surfactant falls in the range 100:40 to 100:2, more preferably 100:30 to 100:5.
- the carrier is water-soluble and the payload is water-insoluble
- an oil-soluble carrier to deliver a contra-soluble (i.e. oil-insoluble) payload into a non-aqueous environment.
- an oil soluble product may use a mixed aqueous/non-aqueous solvent for the water soluble payload material (as in type III). In the alternative it may simply use water (as in type IV) provided that the oil soluble carrier is also soluble in water.
- Type III Nano-Dispersible (in Oil) Forms of an Oil-Insoluble Material Using a Mixed Solvent System
- This aspect of the invention provides a method of making a nano-dispersion of oil-insoluble material in an oil-soluble carrier material comprising the steps of:
- Suitable aqueous solvents include water and electrolyte solutions.
- Suitable carrier materials include preferred water-soluble polymers, preferred water-soluble surfactants and preferred water-soluble inorganic materials.
- the surfactants and the polymers are the preferred carriers as these have adequate solubility in water and an adequate solubility in non-aqueous solvents.
- Particularly preferred carriers include poly-ethylene glycol (PEG), poly-vinyl pyrrolidone (PVP), alkoxylated non-ionic's (especially the PEG/PPG PluronicTM materials), and mixtures thereof.
- PEG poly-ethylene glycol
- PVP poly-vinyl pyrrolidone
- alkoxylated non-ionic's especially the PEG/PPG PluronicTM materials
- non-aqueous solvents Particular examples of non-aqueous solvents, payload materials soluble in the aqueous solvent and carrier materials also soluble in the solvent are provided in Table 3 below.
- Non-limiting examples of oil- Oil-soluble insoluble payload Solvents for the carriers also materials carrier soluble in water Sodium Sulphate Water PVP PEG-PPG-PPG Poly vinyl alcohol Water PEG-PPG-PEG PVP
- These products are dispersible in non-aqueous solvents (‘oils’) such as chloroform and ethanol to form a nano-dispersion of the payload in the non-aqueous solvent.
- non-aqueous solvents such as chloroform and ethanol
- the process of type III is used to disperse sodium sulphate in a carrier which is a mixture PVP and PEG/PPG
- the resulting product can be dissolved in an oil (such as chloroform, in which sodium sulphate is insoluble) to obtain a nano-dispersion of sodium sulphate in a solution of the carrier in chloroform.
- Type IV Oil-Soluble Forms of an Oil-Insoluble Material Using a Single Solvent System
- This aspect of the invention provides a method of making oil-soluble nano-dispersions of at most sparingly oil-soluble materials in a oil-soluble carrier material preferably comprising the steps of:
- non-aqueous solvents Particular examples of non-aqueous solvents, payload materials soluble in the solvent and carrier materials also soluble in the solvent are provided in Table 4 below.
- oil-insoluble payload material such as propylene glycol
- the solution was spray dried using a Buchi B-290TM bench top spray-dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium and the operating conditions were as follows:
- a dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 10 mg/ml (1.0 wt %, 0.1 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was relatively slow to disperse (approx. 5 minutes).
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- a dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was considerably quicker (than example 1) to disperse (less than 30 seconds).
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- a dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material dispersed at a similar rate to example 2 (less than 30 seconds).
- the dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- the dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- the dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- the dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S. It was found to have two peaks.
- Oil red 0 (Aldrich)
- Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich)
- 2.50 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml DCM. The solution was then spray dried at 90° C.
- the dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- Oil red 0 (Aldrich)
- Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich)
- Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml DCM. The solution was then spray dried at 70° C.
- the dry powder was then dispersed into distilled water giving 1 wt % AzB in dispersion and the nanoparticle size was measured with Malvern Nano-S.
- the dry powder was then dispersed into distilled water giving 1 wt % AzB in dispersion and the nanoparticle size was measured with Malvern Nano-S.
- Block Spray PS nm co- dry In PCL, polymer PVP, DCM, temp.
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- a dry pink powder was obtained after spray drying. This powder redispersed rapidly at a concentration of 1 mg/ml (0.1 wt. %) to produce a dark red/purple, transparent solution. Particle sizing of this dispersion revealed two distributions of particle sizes.
- Viscosity 0.90 cP Particle size (peak 1) 39.3 nm (diameter) Standard deviation (peak 1) ⁇ 5.27 nm PdI (peak 1) 0.0542 Particle size (peak 2) 266 nm (diameter) Standard deviation (peak 2) ⁇ 45.7 nm PdI (peak 2) 0.0482
- the solid components are readily soluble in water at room temperature (21.5° C.).
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- a dry white powder was obtained. This material was redispersed in chloroform at a concentration of approximately 1 mg/ml (0.1 wt %, 0.01 wt % sodium sulphate). This produced an optically clear/transparent dispersion.
- the powder was redispersible in water with a particle size Z average measuring 19.8 nm.
- the powder was redispersible in water with a particle size Z average measuring 166 nm.
- This solution was then spray dried at an inlet temperature of 160° C. and a pump rate of 3.6 ml/min.
- the resulting dry, white/pale brown powder was redispersed in water to produce a clear dispersion at a concentration of 1 mg/ml.
- the dispersions particle size was measured by DLS (see particle size trace below). Z-average (mass based size) was found to be 94.2 nm.
- Tinopal SOPTM Thiee Solvent System/Surfactant Carrier
- Vitamin E Single Solvent/Polymer+Surfactant Carrier
- the resulting solution was spray dried using a Buchi mini B-290 system.
- the Inlet temperature was set at 150° C. and the pump rate adjusted to approximately 3.6 ml/min.
- the product was recovered as a dry white powder which was redispersed in water to a concentration of 1 mg/ml and the particle size was measured using a Malvern Nano-S and found to be 17 nm (Zave)
- Vitamin E Acetate Single Solvent/Polymer+Surfactant Carrier
- the resulting solution was spray dried using a Buchi mini B-290 system.
- the Inlet temperature was set at 150° C. and the pump rate adjusted to approximately 3.6 ml/min.
- the product was recovered as a dry white powder which was redispersed in water to a concentration of 1 mg/ml and the particle size was measured using a Malvern Nano-S and found to be 94 nm (Zave)
Abstract
Description
- The present invention relates to dried compositions which form so-called ‘nano dispersions’ when placed in water or other solvents and deliver a material which is not normally soluble in water or said other solvent.
- Many potentially useful materials are insoluble or at best only sparingly soluble in water. This places significant limits on their usefulness or requires that they are used in combination with solvents which almost always more expensive than water and which may have physiological incompatibilities or environmental negatives.
- Our co-pending applications including GB 0501835.3 relate to the use of emulsions of immiscible solvents to prepare a poorly soluble material in a form that is rapidly dispersible. In the above-mentioned applications a ‘carrier’ material (such as a surfactant or a polymer) is dissolved in an aqueous solvent (typically water) and a water-insoluble ‘payload’ material is dissolved in a non-aqueous solvent. An emulsion of the aqueous and non-aqueous solutions is prepared and then dried, such as by freeze or spray drying, to form a material which is believed to comprise a nano-scale dispersion of an insoluble ‘payload’ material in a soluble matrix formed from the ‘carrier’ material.
- A similar approach can be used to provide oil-insoluble payload materials which are rapidly dispersible in oils and other non-aqueous solvents by forming a nano-dispersion of these payload materials in an oil-soluble carrier.
- When the dried powder material obtained from the emulsion is placed in water, the matrix of carrier material dissolves releasing the nano-disperse payload material. This forms a solution-like ‘nano-dispersion’ of the supposedly water-insoluble payload material.
- For ease of reference the payload and the carrier are referred to in the present specification as ‘contra-soluble’ where one is soluble in water (or aqueous solution) and the other is effectively insoluble in water (or aqueous solution) but is soluble in some at least partially non-aqueous solvent.
- There is a need to improve upon this process by simplifying the formation of the emulsion and the drying step.
- WO 2005/011636 discloses a non-emulsion based spray drying process for forming ‘solid amorphous dispersions’ of drugs in polymers. In this method a polymer and a low-solubility drug are dissolved in a solvent and spray-dried to form dispersions in which the drug is mostly present in an amorphous form rather than in a crystalline form. The product form is believed to be a solid solution. That is, both the drug and the polymer are present in a single, undifferentiated phase. Solid solutions are believed to form only at particular component ratios and there is therefore little formulation flexibility with these systems.
- We have now determined that an improvement to the known process is obtained if single or miscible solvents which comprise a single phase are used instead of mixtures of immiscible aqueous/non-aqueous solvents that can form an emulsion.
- Accordingly the present invention provides a process for making contra-soluble nano-dispersions of at most sparingly-soluble materials in a soluble carrier material comprising the steps of:
- (i) providing a single phase mixture of:
- a) a solvent or a mixture of miscible solvents,
- b) at least one carrier material soluble in solvent (a), said carrier material being also contra-soluble to payload material (c) and solid at ambient temperature,
- c) at least one payload material which is soluble in solvent (a), and,
- (ii) drying the mixture to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload (c) dispersed therein as nanoparticles.
- In the context of the present invention, “insoluble” as applied to payload means that its solubility in the target environment is less than 10 g/L at ambient temperature. For water-insoluble payload materials this would be a solubility of less than 10 g/L in water. In the context of the present invention nanoparticles are particles which are smaller than one micron and larger than 1 nm.
- Payload materials preferably have a normal solubility (from a solid or powder form) at ambient temperature (20 Celsius) in their target environment of less than 5 g/L preferably of less than 1 g/L, especially preferably less than 120 mg/L, even more preferably less than 15 mg/L and most preferably less than 5 mg/L.
- In the compositions obtained by process of the present invention the carrier material (b) and the payload (c) are not present in the same phase after drying. The payload is believed to be present as a nanoparticle phase dispersed through a continuous phase of the carrier material.
- The preferred method of particle sizing for the dispersed products of the present invention employs a dynamic light scattering instrument (“Nano S”, manufactured by Malvern Instruments UK). Specifically, the Malvern Instruments Nano S uses a red (633 nm) 4 mW Helium-Neon laser to illuminate a standard optical quality UV curvette containing a suspension of material. The particle sizes quoted in this application are those obtained with that apparatus using the standard protocol. Particle sizes in solid products are the particle sizes inferred from the measurement of the particle size obtained by solution of the solid form and subsequent measurement of the particle size.
- In the present application the term ‘ambient temperature’ means 20 degrees Celsius and all percentages are percentages by weight unless otherwise specified.
- By using the process as described herein, and an appropriate choice of carrier, it is possible to form a solid matrix that is soluble in a particular aqueous or non-aqueous solvent and which releases the payload (which is insoluble in the particular solvent dissolving the matrix) to form a liquid nano-dispersion of the payload material in the solvent.
- In this specification ‘drying’ means the removal of such aqueous and non-aqueous solvents as are present. Typically, the drying process is conducted above ambient temperature. Most preferably, the drying process is a spray-drying process. Less preferable alternatives to spray-drying include freeze-drying which is conducted below ambient temperature. The feedstock to the dryer is essentially free of solids (when at ambient temperature). Where solids are present in the dryer feedstock these should not comprise more than 10%, preferably not more that 5% of the feedstock.
- In one alternative form of the invention a non-aqueous solvent is employed in which both the payload and the carrier are soluble. This solvent can comprise a single solvent species or a mixture of solvent species. Preferred solvents are polar, protic or aprotic solvents. Generally preferred solvents have a dipole moment greater than 1 and a dielectric constant greater than 4.5.
- Particularly preferred solvents are selected from the group consisting of haloforms (preferably dichloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and other water miscible species comprising a hetroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide).
- In an alternative form of the invention a mixture of miscible solvents are used in which mixture both the payload and the matrix are soluble, and wherein at least one of the solvents is an aqueous solvent and at least another solvent is a non-aqueous solvent. Preferably, the non-aqueous solvent is selected from one or more of the polar protic or polar aprotic solvents listed above.
- It is also possible to use a solvent which comprises only an aqueous phase provided it can dissolve both an oil-insoluble payload material and a carrier which is also oil-soluble. This method is used for the production of materials which comprise a nano-dispersion of a water-soluble material in an oil-soluble carrier.
- Solvent systems employed in the present invention are not limited to binary mixtures, but can include three or more components. Additional water-immiscible solvents can be present provided that they are miscible in the solvent mixture as a whole. These additional water-immiscible solvents need not fulfill the conditions as regards either dipole moment and/or dielectric constant as given above and include, for example, linear hydrocarbons (preferably hexane), cyclic hydrocarbons (preferably cyclohexane), halocarbons (preferably carbon tetrachloride, methylene chloride) and ethers (preferably diethyl ether). While the ‘carrier’ and the ‘payload’ material are both soluble in a single phase (which can be a single solvent or a mixture of solvents) the use of an emulsion in the drying process is not altogether excluded as other materials may be present which are not miscible provided that there exists at least one single phase which comprises both the carrier and the payload.
- Where a mixture of solvents is used it is not necessary that the solvents are mixed before the carrier and the payload material are dissolved therein. It is possible to dissolve the carrier and the payload in different solvents which are then mixed prior to the drying step.
- Preferably the solvents present are removed simultaneously, rather than sequentially, in a single drying step.
- Ideally, where an insoluble payload is being delivered into an aqueous environment, the carrier material is rapidly soluble in water as well as in the solvent or solvent mixtures used to form the feed for the drying step. Thus, when the solid product is placed in an aqueous environment, the carrier will quickly dissolve and release the payload material in nano-disperse form.
- Where the carrier will deliver a material that is water-soluble into a non-aqueous environment, the carrier should preferably be rapidly soluble in that environment. In the present specification the term ‘oil’ is used to indicate a non-aqueous environment. Thus, when the solid product is placed in oil, the carrier will quickly dissolve and release the payload material in a nano-disperse form.
- As noted above, typical particle sizes for the dispersed form of the payload material after delivery may be determined by use, for example, of a Malvern™ ‘Nano-S’ apparatus. Results generally fall into the range from 500-2 nm (expressed as a diameter) and this particle size range is preferred, with 300-4 nm being particularly preferred. For comparative purposes, the range is analogous to the size of a virus particle (which typically range from 450-20 nm). The size distribution may show more than one peak. Thus, as noted above, the “solutions” obtained are not true solutions comprising a material dispersed on a molecular scale but are nano-scale dispersions in which the ‘soluble’ material retains some organized structure but on such a small scale that it has many of the properties of a true solution. For example, dispersing a water-insoluble bleach from products of the present invention results in the bleach being more finely dispersed and reduces the spot damage seen when larger water-insoluble particles of the bleach contact a fabric.
- It is believed that, especially in the case of non-polymers, many of the particles of ‘payload’ materials present both in the dry (solvent free) form and the re-dispersed product are substantially crystalline materials. This can be seen by X-ray powder diffraction, which has shown diffraction patterns in the dried material characteristic of a crystalline structure. Preferably more that 50% of the payload material is in a crystalline form.
- Differential scanning calorimetry of the dried material has also shown melting behavior which is indicative of the presence of organized structures. From these results, it is believed that the compositions of the invention are not solid solutions, but comprise a nano-scale, phase-separated mixture. Moreover, the compositions of the present invention can be varied as regards the ratios of the carrier and the payload, again indicating that they are not solid solutions which are generally only formed at specific component ratios.
- The invention will be further described below with reference to certain preferred features. As noted above, the invention uses a carrier and a payload which are “contra-soluble” in water and a non-aqueous solvent. Within the generality of the present invention are four specific sub-groups of embodiments. These can be briefly described as follows:
- A process for preparing a form of a water-insoluble material which is dispersible in water using a mixed aqueous/non-aqueous solvent system,
- A process for preparing a form of a water-insoluble material which is dispersible in water using an anhydrous solvent system,
- A process for preparing a form of an oil-insoluble material which is dispersible in oil using a mixed aqueous/non-aqueous solvent system, and,
- A process for preparing a form of an oil insoluble material which is dispersible in oil using a wholly aqueous solvent system.
- The types of process I to IV will each be described in further detail below. Types I and II are the preferred processes. It will be noted that in both I and II water soluble carrier materials and water insoluble payload materials are used. Preferred payload and carrier materials for processes of types I and II are described if further detail below.
- Some specific examples of water-insoluble ‘payload’ materials are given below. These are given as examples only and are not intended to limit the applicability of the present invention. Those skilled in the art will however realize that the materials of the present invention will have utility in other areas not specifically exemplified herein.
- Water insoluble (hydrophobic) materials that are released from the products obtained by the process of the present invention at the time of use and can be utilized in the process of the present invention preferably include:—
-
- antimicrobial agents: for example: Triclosan™, climbazole, octapyrox, ketoconazole, propiconazole, phthalimo-peroxyhexanoic acid (PAP), quaternary ammonium compounds;
- antidandruff agents: for example: zinc pyrithione;
- skin lightening agents, for example 4-ethylresorcinol;
- fluorescing agents: for example: 2,5-bis(2-benzoxazolyl)thiophene for use on fabrics (such as cotton, nylon, polycotton or polyester) in laundry products;
- skin conditioning agents: for example: cholesterol;
- antifoaming agents: for example: isoparrafin
- hair conditioning agents: for example: quaternary ammonium compounds, protein hydrolysates, peptides, ceramides and hydrophobic conditioning oils for example hydrocarbon oils such as paraffin oils and/or mineral oils, fatty esters such as mono-, di-, and triglycerides, silicone oils such as polydimethylsiloxanes (e.g. dimethicone) and mixtures thereof;
- fabric conditioning agents: for example: quaternary ammonium compounds having 1 to 3, preferably 2 optionally substituted (C8-C24) alk(en)yl chains attached to the nitrogen atom by one or more ester groups; hydrophobic monoparticles such as a sucrose polyester for example sucrose tetra-tallowate; silicones for example polydimethylsiloxane;
- thickening agents: for example: hydrophobically modified cellulose ethers such as modified hydroxyethyl-celluloses;
- dyes and colouring agents: for example: dyes intended to change the colour of fabrics, fibres, skin or hair;
- UV protecting agents: such as sunscreens for example: octyl methoxycinnamate (Parsol MCX), butyl methoxydibenzoylmethane (Parsol 1789) and benzophenone-3 (Uvinul M-40), ferulic acid;
- bleach or bleach precursors: for example: 6-N-phthalimidoperoxyhexanoic acid (PAP) or photobleaching compounds.
- Antioxidants: for example: hydrophobic vitamins such as vitamin E, retinol, antioxiants based on hydroxytoluene such as Irganox™ or commercially available antioxidants such as the Trollox™ series.
- Insecticides (for example lamda-cyhalothin), pesticides, herbicides and other agrochemicals, in particular, those that are stored as solid compositions before use but which are made up into liquid for spraying (or other application) onto animals or crops (for example lamda-cyhalothin),
- perfumes or flavourings or precursors thereto;
- pharmaceutically or veterinary active materials;
- a Vitamins/nutraceuticals
- Whether a type I or a type II process is used will depend on whether the water-insoluble payload material is soluble in a wholly non-aqueous solvent or a water-containing mixture of solvents. If the payload material is only soluble in a mixture containing water then the type I process (mixed aqueous/non-aqueous solvents) must be used.
- Suitable carrier materials include the preferred water-soluble polymers, preferred water-soluble surfactants and preferred water-soluble inorganic materials as described in further detail below. These lists are not exhaustive as other water-soluble materials, for example citric acid, can be used.
- Carrier materials for processes of types I and II are water soluble as well as being soluble in at least one of the aqueous/non-aqueous solvent system of type I processes or the anhydrous solvent system of type II processes. As these materials are all water-soluble they will generally be soluble in the solvent combinations of the type I process.
- Examples of suitable water-soluble polymeric carrier materials include:
- (a) natural polymers (for example naturally occurring gums such as guar gum, alginate locust bean gum or a polysaccharide such as dextran;
- (b) cellulose derivatives for example xanthan gum, xyloglucan, cellulose acetate, methylcellulose, methyl-ethylcellulose, hydroxy-ethylcellulose, hydroxy-ethylmethyl-cellulose, hydroxy-propylcellulose, hydroxy-propylmethylcellulose, hydroxy-propylbutylcellulose, ethylhydroxy-ethylcellulose, carboxy-methylcellulose and its salts (eg the sodium salt—SCMC), or carboxy-methylhydroxyethylcellulose and its salts (for example the sodium salt);
- (c) homopolymers of or copolymers prepared from two or more monomers selected from: vinyl alcohol, acrylic acid, methacrylic acid, acrylamide, methacrylamide, acrylamide methylpropane sulphonates, aminoalkylacrylates, aminoalkyl-methacrylates, hydroxyethylacrylate, hydroxyethylmethylacrylate, vinyl pyrrolidone, vinyl imidazole, vinyl amines, vinyl pyridine, ethyleneglycol and other alkylene glycols, ethylene oxide and other alkylene oxides, ethyleneimine, styrenesulphonates, ethyleneglycolacrylates and ethyleneglycol methacrylate
- (d) cyclodextrins, for example beta-cyclodextrin
- (e) mixtures thereof.
- When the polymeric material is a copolymer it may be a statistical copolymer (heretofore also known as a random copolymer), a block copolymer, a graft copolymer or a hyperbranched copolymer. Comonomers other than those listed above may also be included in addition to those listed if their presence does not destroy the water soluble or water dispersible nature of the resulting polymeric material.
- Examples of suitable and preferred homopolymers include poly-vinylalcohol, poly-acrylic acid, poly-methacrylic acid, poly-acrylamides (such as poly-N-isopropylacrylamide), poly-methacrylamide; poly-acrylamines, poly-methyl-acrylamines, (such as polydimethylaminoethylmethacrylate and poly-N-morpholinoethylmethacrylate), polyvinylpyrrolidone, poly-styrenesulphonate, polyvinylimidazole, polyvinylpyridine, poly-2-ethyl-oxazoline poly-ethyleneimine and ethoxylated derivatives thereof.
- Polyethylene glycol (PEG), Polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl celluose and/or hydroxypropyl methyl-cellulose (HPMC) are particularly preferred polymer carrier materials.
- Where the carrier material is a surfactant, the surfactant may be non-ionic, anionic, cationic, amphoteric or zwitterionic.
- Examples of suitable non-ionic surfactants include ethoxylated triglycerides; fatty alcohol ethoxylates; alkylphenol ethoxylates; fatty acid ethoxylates; fatty amide ethoxylates; fatty amine ethoxylates; sorbitan alkanoates; ethylated sorbitan alkanoates; alkyl ethoxylates; Pluronics™; alkyl polyglucosides; stearol ethoxylates; alkyl polyglycosides.
- Examples of suitable anionic surfactants include alkylether sulfates; alkylether carboxylates; alkylbenzene sulfonates; alkylether phosphates; dialkyl sulfosuccinates; alkyl sulfonates; soaps; alkyl sulfates; alkyl carboxylates; alkyl phosphates; paraffin sulfonates; secondary n-alkane sulfonates; alpha-olefin sulfonates; isethionate sulfonates.
- Examples of suitable cationic surfactants include fatty amine salts; fatty diamine salts; quaternary ammonium compounds; phosphonium surfactants; sulfonium surfactants; sulfonxonium surfactants.
- Examples of suitable zwitterionic surfactants include N-alkyl derivatives of amino acids (such as glycine, betaine, aminopropionic acid); imidazoline surfactants; amine oxides; amidobetaines.
- Mixtures of surfactants may be used. In such mixtures there may be individual components which are liquid, provided that the carrier material overall, is a solid.
- Alkoxylated nonionic's (especially the PEG/PPG eg Pluronic™ materials and/or the PEG/alcohol nonionics and/or aromatic nonionics, including phenol-ethoxylates (especially Triton™ materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the Span™ and Tween™ types) and cationics (especially cetyltrimethylammonium bromide—CTAB) are particularly preferred as surfactant carrier materials.
- In the type I and type II process the carrier material can also be a water-soluble inorganic material which is neither a surfactant not a polymer. Simple organic salts have been found suitable, particularly in admixture with polymeric and/or surfactant carrier materials as described above. Suitable salts include carbonate, bicarbonates, halides, sulphates, nitrates and acetates, particularly soluble salts of sodium, potassium and magnesium. Preferred materials include, sodium carbonate, sodium bicarbonate and sodium sulphate. These materials have the advantage that they are cheap and physiologically acceptable. They are also relatively inert as well as compatible with many materials found in household and pharmaceutical products.
- Mixtures of carrier materials are advantageous.
- For the type I and type II process, preferred mixtures include combinations of inorganic salts and surfactants and, in particular, mixtures of polymers and surfactants. Particularly preferred mixtures include combinations of surfactants and polymers which include at least one of:
- a) Polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), poly(2-ethyl-2-oxazaline), polyvinyl alcohol (PVA) hydroxypropyl cellulose and hydroxypropyl-methyl cellulose (HPMC), alginates and mixtures thereof,
and, at least one of; - b) alkoxylated nonionic's (especially the PEG/PPG Pluronic™ materials), phenol-ethoxylates (especially TRITON™ materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the Span™ and Tween™ types), cationics (especially cetyltrimethylammonium bromide—CTAB), and mixtures thereof.
- In preferred forms of the invention the level of surfactant carrier is such that at least 50% of the total carrier is surfactant. Mixtures having a majority of surfactant present over the other carriers exhibit enhanced payload effects.
- Both processes of types I and II use a non-aqueous solvent (or a mixture of said solvents).
- Particularly preferred solvents are selected from the group consisting of haloforms (preferably di-chloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and other water miscible species comprising hetroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide). Mixtures of the aforementioned may also be employed.
- Preferred solvents include dichloromethane, chloroform, ethanol, acetone and dimethyl sulphoxide.
- Preferred non-aqueous solvents have a boiling point of less than 150 Celsius and, more preferably, have a boiling point of less than 100 Celsius, so as to facilitate drying, particularly spray-drying under practical conditions and without use of specialised equipment. Preferably they are non-flammable, or have a flash point above the temperatures encountered in the method of the invention.
- Process of types I and II are described in further detail below:
- This aspect of the invention provides a process for making a nano-dispersion of a water-in soluble material in a water-soluble carrier material comprising the steps of:
- (i) providing a mixture of:
- a) an aqueous solvent for a carrier material;
- b) at least one water-soluble carrier material soluble in the mixture of aqueous solvent (a) and second solvent (c), said carrier material being solid at ambient temperature,
- c) at least one non-aqueous second solvent said second solvent being miscible with aqueous solvent (a) to form a mixed solvent capable of dissolving carrier material (b) and payload (d), and;
- d) a payload material which is dispersible or soluble in the mixture of aqueous solvent (a) and non-aqueous solvent (c) but not in aqueous solvent (a) alone, and;
- (ii) drying the mixture at above ambient temperature to remove solvents (a) and (c) and thereby obtain the carrier material (b) in a solid form with payload (d) dispersed therein in a nanoparticulate form, wherein the product of the drying step is water dispersible to give an aqueous solution of (b) and an aqueous nano dispersion of (d).
- The preferred aqueous solvent is water. Electrolyte solutions can also be used as the aqueous solvent.
- Particular examples of water miscible non-aqueous solvents, payload materials soluble in the solvent and water-soluble carrier materials also soluble in a mixture of the solvent and an aqueous solution are provided in Table 1 below.
-
TABLE 1 Water-miscible solvents to make water soluble products Non-limiting Water-soluble examples of Water-miscible non- carriers soluble water-insoluble aqueous solvents in mixture of pay load for the payload solvent and materials material aqueous solution Triclosan Ethanol SDS Acetone Isopropyl alcohol Sudan Red 7B Acetone SDS - This aspect of the invention provides a process for making water-soluble nano-dispersions of at most sparingly water-soluble materials in a water-soluble carrier material comprising the steps of:
- (i) providing a mixture of:
- a) a non-aqueous solvent or a mixture of miscible non-aqueous solvents,
- b) at least one carrier material soluble in non-aqueous solvent (a), said carrier material being also soluble in water and solid at ambient temperature,
- c) at least one water-insoluble payload material which is soluble in non-aqueous solvent (a), and,
- (ii) drying the mixture above ambient temperature to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload material (c) dispersed therein in a nanoparticulate form, wherein the product of the drying step is water dispersible to give an aqueous solution of (b) and an aqueous nano dispersion of (c).
- Suitable carrier materials include the preferred water-soluble polymers and preferred water-soluble surfactants as mentioned above which are also soluble in the anhydrous non-aqueous solvent (or solvent mixture)
- Particularly preferred carrier materials for use in process type II are:
- a) polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA) hydroxypropyl cellulose (HPC) and hydroxypropyl-methyl cellulose (HPMC) preferably in combination with at least one of;
- b) alkoxylated non-ionic's (especially the PEG/PPG Pluronic™ materials), phenol-ethoxylates (especially TRITON™ materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the Span™ and Tween™ types) and cationics (especially cetyltrimethylammonium bromide—CTAB)
- Particularly preferred solvents are haloforms for use in process type II (preferably di-chloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and species comprising a hetroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide). Mixtures of the aforementioned may also be employed.
- The presence of some low level of water in the non-aqueous solvent is not excluded, as a cheaper technical grade of the solvent may be used rather than a more expensive analytical grade. Preferably the level of water is below 1%.
- Particular examples of non-aqueous solvents, payload materials soluble in the solvent and carrier materials also soluble in the solvent are provided in Table 2 below.
-
TABLE 2 Single phase solvents/carriers to make water “soluble” products Non-limiting Water- examples of water- immiscible non- Water-soluble insoluble payload aqueous carriers soluble in materials solvents solvent Chlorothalonil Chloroform PVP (fungicide) PEG-PPG Amphomer Resin Ethanol Hydroxy propyl (Resin-AM) cellulose Azoxystrobin dichloromethane PVP Phenol-ethoxylate Azoxystrobin dichloromethane PVP PEG-PPG Divanillin DMSO PVP HPC Polycaprolactone DCM PVP PEG-PPG 1-Napthylamine DCM PVP PEG-PPG Lambda Cyhalothrin DCM PPV PEG-PPG Homoeriodictol DMSO PVP HPC Sudan Red Chloroform PEG-PPG Oil Red O(dyes) Dichloromethane PVP - These combinations of materials give a product which is dispersible in water to form a nano-dispersion of the water-insoluble payload material.
- Some materials exhibit a low solubility in both aqueous and non-aqueous solvents (examples are Homoeriodictyol and divanillin), both of which are insoluble in water, ethanol and poly-propylene glycol. However these both materials are soluble in DMSO. By selection of a carrier which is also soluble in both DMSO and one of water, ethanol and PPG (for example PVP/HPC) it is possible to obtain a nano-disperse form of either payload material in the carrier, which can be “dissolved” in water, ethanol or PPG.
- Spray drying, the most preferred method of drying, is well known to those versed in the art. In the case of the present invention some care must be taken due to the presence of a volatile non-aqueous solvent in the feedstock being dried. In order to reduce the risk of explosion when a flammable solvent is being used, an inert gas, for example nitrogen, can be employed as the drying medium in a so-called closed spray-drying system. The solvent can be recovered and re-used.
- We have found that the ‘Buchi’ B-290 type laboratory spray drying apparatus is suitable.
- It is preferable that the drying temperature should be at or above 100 Celsius, preferably above 120 Celsius and most preferably above 140 Celsius. Elevated drying temperatures have been found to give smaller particles in the re-dissolved nano-disperse material.
- In addition to the non-aqueous solvent an optional co-surfactant may be employed in the composition prior to the drying step. We have determined that the addition of a relatively small quantity of a volatile cosurfactant reduced the particle diameter of the material produced. This can have a significant impact on particle volume. For example, reduction from 297 nm to 252 nm corresponds to a particle size reduction of approximately 40%. Thus, the addition of a small quantity of co-surfactant offers a simple and inexpensive method for reducing the particle size of materials according to the present invention without changing the final product formulation.
- Preferred co-surfactants are short chain alcohols or amine with a boiling point of <220° C.
- Preferred co-surfactants are linear alcohols. Preferred co-surfactants are primary alcohols and amines. Particularly preferred co-surfactants are selected from the group consisting of the 3-6 carbon alcohols. Suitable alcohol co-surfactants include n-propanol, n-butanol, n-pentanol, n-hexanol, hexylamine and mixtures thereof.
- Preferably the co-surfactant is present in a quantity (by volume) less than the solvent preferably the volume ratio between the solvent and the co-surfactant falls in the range 100:40 to 100:2, more preferably 100:30 to 100:5.
- In addition to the processes in which the carrier is water-soluble and the payload is water-insoluble, it is also possible to use an oil-soluble carrier to deliver a contra-soluble (i.e. oil-insoluble) payload into a non-aqueous environment.
- As with the processes of types I and II for making water soluble/dispersible products, the process used to obtain an oil soluble product may use a mixed aqueous/non-aqueous solvent for the water soluble payload material (as in type III). In the alternative it may simply use water (as in type IV) provided that the oil soluble carrier is also soluble in water. These processes of types III and IV are described in further detail below.
- This aspect of the invention provides a method of making a nano-dispersion of oil-insoluble material in an oil-soluble carrier material comprising the steps of:
- (i) providing a mixture of:
- a) a non-aqueous solvent for a carrier material,
- b) an oil-soluble carrier material which is also soluble in the mixture of non-aqueous solvent (a) and aqueous solvent (c), said carrier material being solid at ambient temperature,
- c) a second aqueous solvent for a payload material, said aqueous solvent being miscible with non-aqueous solvent (a), and,
- d) a payload material which is soluble in the mixture of solvents (a) and (c) but not in (a) alone, and,
- (ii) drying the mixture above ambient temperature to simultaneously remove solvents (a) and (c) and thereby obtain the carrier material (b) in a solid form with the payload (d) dispersed therein in a nanoparticulate form, wherein the product of the drying step is oil dispersible to give an oil solution of (b) and a nano dispersion of (c).
- Suitable aqueous solvents include water and electrolyte solutions.
- Suitable carrier materials (referred to herein as ‘water soluble carrier materials’) include preferred water-soluble polymers, preferred water-soluble surfactants and preferred water-soluble inorganic materials. Of the preferred carrier materials mentioned above, the surfactants and the polymers are the preferred carriers as these have adequate solubility in water and an adequate solubility in non-aqueous solvents.
- Particularly preferred carriers include poly-ethylene glycol (PEG), poly-vinyl pyrrolidone (PVP), alkoxylated non-ionic's (especially the PEG/PPG Pluronic™ materials), and mixtures thereof.
- Particular examples of non-aqueous solvents, payload materials soluble in the aqueous solvent and carrier materials also soluble in the solvent are provided in Table 3 below.
-
TABLE 3 Solvents/Carriers to make “oil soluble” products Non-limiting examples of oil- Oil-soluble insoluble payload Solvents for the carriers also materials carrier soluble in water Sodium Sulphate Water PVP PEG-PPG-PPG Poly vinyl alcohol Water PEG-PPG-PEG PVP - These products are dispersible in non-aqueous solvents (‘oils’) such as chloroform and ethanol to form a nano-dispersion of the payload in the non-aqueous solvent. By way of example, if the process of type III is used to disperse sodium sulphate in a carrier which is a mixture PVP and PEG/PPG, then the resulting product can be dissolved in an oil (such as chloroform, in which sodium sulphate is insoluble) to obtain a nano-dispersion of sodium sulphate in a solution of the carrier in chloroform.
- This aspect of the invention provides a method of making oil-soluble nano-dispersions of at most sparingly oil-soluble materials in a oil-soluble carrier material preferably comprising the steps of:
- (i) providing a mixture of:
- a) an aqueous solvent,
- b) a carrier material soluble in aqueous solvent (a), said carrier material being also soluble in oil and solid at ambient temperature,
- c) an oil-insoluble payload material which is soluble in aqueous solvent (a), and,
- (ii) drying the mixture above ambient temperature to remove (a) and thereby obtain the material (b) in solid form with (c) dispersed therein in a nanoparticulate form, wherein the product of the drying step is oil-dispersible to give an oil solution of (b) and a nano dispersion of (c).
- Particular examples of non-aqueous solvents, payload materials soluble in the solvent and carrier materials also soluble in the solvent are provided in Table 4 below.
-
TABLE 4 Single phase solvents to make oil soluble products Non-limiting examples of oil- Oil-soluble insoluble payload carriers soluble materials Aqueous solvents in solvent Poly vinyl alcohol Water Hydroxypropyl cellulose PVP - These materials enable the formation of a material from which the oil-insoluble payload material is dispersible in an ‘oil’ (such as propylene glycol) to form a nano-dispersion.
- In order that the present invention may be further understood it is further explained below with reference to specific examples and embodiments.
- All the particle size measurements are identical; where 1 mg spray dried powder was dispersed into 1 ml distilled water. The dispersion was vortex mixed before DLS measurement. All the particle size data were quoted as Z-average.
- A solution was prepared of the following:
-
-
Chlorothalonil 0.2 g (10 wt. %) PEG-PPG-PEG 0.4 g (20 wt. %) PVP (90 kDa) 1.4 g (70 wt. %) Chloroform 40 ml - At these concentrations, the solid components were readily soluble in the chloroform at the measured room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290™ bench top spray-dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium and the operating conditions were as follows:
-
Pump rate 10% (3.6 ml/min) Inlet temperature 105° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 10 mg/ml (1.0 wt %, 0.1 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was relatively slow to disperse (approx. 5 minutes).
- The resulting solution had the following properties:
-
Viscosity 1.95 cP Particle size 437 nm (diameter) Standard deviation ±25.5 nm PdI 0.385 -
-
Chlorothalonil 0.2 g (10 wt. %) PEG-PPG-PEG 0.4 g (20 wt. %) PVP (55 kDa) 1.4 g (70 wt. %) Chloroform 40 ml - At these concentrations, the solid components are readily soluble in chloroform at room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 15% (5.4 ml/min) Inlet temperature 90° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was considerably quicker (than example 1) to disperse (less than 30 seconds).
-
Viscosity 1.0 cP Particle size 452 nm (diameter) Standard deviation ±5.72 nm PdI 0.181 -
-
Chlorothalonil 0.05 g (10 wt. %) PEG-PPG-PEG 0.1 g (20 wt. %) PVP (55 kDa) 0.35 g (70 wt. %) Chloroform 30 ml - At these concentrations, the solid components are readily soluble in chloroform at room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 15% (5.4 ml/min) Inlet temperature 90° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material dispersed at a similar rate to example 2 (less than 30 seconds).
-
Viscosity 0.93 cP Particle size 402 nm (diameter) Standard deviation ±15.1 nm PdI 0.228 - 0.50 g Sudan red 7B (Aldrich) and 4.50 g Poly(ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol) (Mw 8,400, Aldrich) were dissolved into 50 ml Chloroform. The solution was then spray dried at 90° C.
- The dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- 1.50 g Sudan red 7B (Aldrich) and 3.50 g Poly(ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol) (Mw 8,400, Aldrich) were dissolved into 50 ml Dichloromethane (DCM). The solution was then spray dried at 70° C.
- The dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- 0.50 g Sudan red 7B, 1.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly (ethylene glycol) (Mw 8,400, Aldrich), and 3.50 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml Dichloromethane (DCM). The solution was then spray dried at 90° C.
- The dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- 0.50 g Sudan red 7B, 1.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly (ethylene glycol) (Mw 8,400, Aldrich), and 3.50 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml DCM. The solution was then spray dried at 60° C.
- The dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S. It was found to have two peaks.
- 1.50 g Sudan red 7B, 1.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich), and 2.50 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml DCM. The solution was then spray dried at 90° C.
- The dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S. (WP-123)
- Details concerning examples 4-8 and their results are given in Table 6
-
TABLE 6 Spray dry Sudan red Pluronic, PVP, temp., PS, Ex. 7B, mg/ml mg/ml mg/ml Solvent, ml ° C. nm 4 30.0 70.0 — Chloroform, 70 203 50.0 5 30.0 70.0 — DCM, 50.0 70 290 6 10.0 20.0 70.0 DCM, 50.0 90 66 7 10.0 20.0 70.0 DCM, 50.0 60 172, 50 8 30.0 20.0 50.0 DCM, 50.0 90 110 Spray drying conditions: Aspiration rate: 100%; Pump rate: 3.62 ml/min. - 1.50 g Oil red 0 (Aldrich), 1.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich), and 2.50 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml DCM. The solution was then spray dried at 90° C.
- The dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S.
- 1.50 g Oil red 0 (Aldrich), 1.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich), and 2.50 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml DCM. The solution was then spray dried at 70° C.
- The dry powder was then dispersed into distilled water and the nanoparticle size was measured with Malvern Nano-S. (WP-134)
- Details concerning these experiments and their results are given in Table 7
-
TABLE 7 Oil Red O, Pluronic, PVP, Solvent, Spray dry PS, Ex. mg/ml mg/ml mg/ml ml temp., ° C. nm 9 30.0 20.0 50.0 DCM, 50.0 90 192 10 30.0 20.0 50.0 DCM, 50.0 70 281 Spray drying conditions: Aspiration rate: 100%; Pump rate: 3.62 ml/min. - 1.10 g Azoxystrobin™, 2.00 g Brij® 58 (Aldrich), and 6.90 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 200 ml DCM. The solution was then spray dried at 70° C.
- The dry powder was then dispersed into distilled water giving 1 wt % AzB in dispersion and the nanoparticle size was measured with Malvern Nano-S.
- 5.00 g Azoxystrobin, 10.00 g Poly(ethylene glycol)-block-polypropylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich), and 35.00 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 1.0 litre DCM. The solution was then spray dried at 70° C.
- The dry powder was then dispersed into distilled water giving 1 wt % AzB in dispersion and the nanoparticle size was measured with Malvern Nano-S.
- Details concerning these experiments and their results are given in Table 8
-
TABLE 8 Spray dry AzB, Surfactant, PVP, Solvent, temp., PS, Ex. mg/ml mg/ml mg/ml ml ° C. nm 11 5.5 Brij 58, 10.0 34.5 DCM, 200 70 532 12 5.0 Pluronic, 10.0 35.0 DCM, 1000 70 356 Spray drying conditions: Aspiration rate: 100%; Pump rate: 1.80 ml/min. - 0.50 g Polycaprolactone (PCL, Mw 14,000, Aldrich), 1.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich), and 3.50 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 50 ml DCM. The solution was then spray dried at 90° C. The dry powder was then dispersed into distilled water, ethanol, and water/ethanol mixture (50/50 in volume) and the nanoparticle size was measured with Malvern Nano-S.
- 1.00 g Polycaprolactone (PCL, Mw 14,000, Aldrich) 2.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich), and 2.00 g Polyvinylpyrrolidone (Mw 55,000, Aldrich) were all dissolved into 100 ml DCM. The solution was then spray dried at 90° C. The dry powder was then dispersed into distilled water, ethanol, and water/ethanol mixture (50/50 in volume) and the nanoparticle size was measured with Malvern Nano-S.
- Details concerning these experiments and their results are given in Table 9
-
TABLE 9 Block Spray PS, nm co- dry In PCL, polymer PVP, DCM, temp. In Water/ In Ex mg/ml mg/ml mg/ml ml ° C. water EtOH EtOH 13 10.0 20.0 70.0 50.0 90 106 242 389 14 10.0 20.0 20.0 100.0 90 407 678 832 Spray drying conditions: Aspiration rate: 100%; Pump rate: 3.62 ml/min. - 0.25 g of an Amphomer Resin (28-4910, ex ICI), 0.25 g Klucel® EF (Hydroxypropylcellulose, Mw 80,000, Hercules Inc.), and 4.50 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 100 ml Ethanol. The solution was then spray dried at 100° C. The dry powder was then dispersed into distilled water, and the nanoparticle size was measured with Malvern Nano-S.
- Details concerning these experiments and their results are given in Table 10.
-
TABLE 10 AM, Klucel PVP, EtOH, Spray dry PS, Ex. mg/ml EF, mg/ml mg/ml ml temp., ° C. nm 15 2.5 2.5 45.0 100 100 445 Spray drying conditions: Aspiration rate: 100%; Pump rate: 3.62 ml/min. -
-
Triclosan 2.0 g (20 wt. %) SDS 8.0 g (80 wt. %) Water miscible solvent 125 ml (50/50 v/v mixture) - Three different water miscible organic solvents were employed (ethanol, acetone and isopropyl alcohol). At these concentrations, the solid components are readily soluble in the cosolvent mixture at room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 7% (2.5 ml/min) Inlet temperature 120° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - For each different cosolvent system, a dry white powder was obtained. These material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %), rapidly producing a crystal clear dispersion that remained stable for more than 12 hours. All the dispersions appeared to produce particles of the similar sizes and distributions.
- Details concerning these experiments and their results are given in Table 11.
-
TABLE 11 particle Poly Particle Poly size SD dispersity size SD dispersity Residual TCN Viscosity peak 1 peak 1 index peak 2 peak 2 index wt. % Cosolvent (cP) (d · nm) (d · nm) peak 1 (d · nm) (d · nm) peak 2 (UV) Ethanol 0.9 3.5 0.088 0.0674 187 28.2 0.1829 13.6 Acetone 0.9 3.01 0.061 0.0504 127 15.8 0.2605 14.8 IPA 0.9 3.06 0.045 0.0487 179 16.5 0.1957 17 -
-
Sudan Red 7B 0.2 g (4.8 wt. %) SDS 4.0 g (95.2 wt. %) Water/Acetone 200 ml (50/50 v/v mixture) - Addition of the cosolvents produced a dark red solution. However, there still appeared to be a very small quantity of undissolved Sudan Red. Therefore, the solution was filtered through a standard Whatman Number 1 filter paper, prior to spray drying.
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 7% (2.5 ml/min) Inlet temperature 120° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry pink powder was obtained after spray drying. This powder redispersed rapidly at a concentration of 1 mg/ml (0.1 wt. %) to produce a dark red/purple, transparent solution. Particle sizing of this dispersion revealed two distributions of particle sizes.
-
Viscosity: 0.90 cP Particle size (peak 1) 39.3 nm (diameter) Standard deviation (peak 1) ±5.27 nm PdI (peak 1) 0.0542 Particle size (peak 2) 266 nm (diameter) Standard deviation (peak 2) ±45.7 nm PdI (peak 2) 0.0482 -
-
Sodium Sulphate 1.0 g (10 wt. %) PEG-PPG-PEG 2.0 g (20 wt. %) PVP (30 kDa) 7.0 g (70 wt. %) Water 200 ml - At these concentrations, the solid components are readily soluble in water at room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 10% (3.7 ml/min) Inlet temperature 120° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry white powder was obtained. This material was redispersed in chloroform at a concentration of approximately 1 mg/ml (0.1 wt %, 0.01 wt % sodium sulphate). This produced an optically clear/transparent dispersion.
-
Viscosity 0.80 cP Particle size 366 nm (diameter) N.B. there are clearly two other smaller particle size distributions at around 10 nm and 60 nm. However, the larger 366 nm peak represents the majority of the particle mass. Standard deviation ±53.4 nm - 0.50 g Polyvinyl alcohol (PVA, Mw 10,000, Aldrich), 1.00 g Poly(ethylene glycol)-block-poly (propylene glycol)-block-poly(ethylene glycol) (Mw 8,400, Aldrich), and 8.50 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 50 ml water and 50 ml ethanol cosolvent. The solution was then spray dried at 90° C. The dry powder was then dispersed into ethanol (EtOH) and the nanoparticle size was measured with Malvern Nano-S. (SP-1)
- 0.50 g Polyvinyl alcohol (PVA, Mw 10,000, Aldrich), 1.00 g Klucel® EF (Mw 80,000, Hercules Incorporated), and 8.50 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 100 ml distilled water. The solution was then spray dried at 150° C. The dry powder was then dispersed into propylene glycol (PPG) and the nanoparticle size was measured with Malvern Nano-S. (SP-2)
- Details concerning these experiments and their results are given in Table 12.
-
TABLE 12 PVA, Surfactant, PVP, Solvent, Spray dry PS, nm Example mg/ml mg/ml mg/ml ml temp., ° C. EtOH PPG 21 5.0 Pluronic, 85.0 H2O, 90 250 N/A 10.0 50/EtOH, 50 22 5.0 HPC, 10.0 85.0 H2O, 100 150 N/A 326 Spray drying conditions: Aspiration rate: 100%; Pump rate: 1.80 ml/min. - 3.00 g Homoeriodictyol, 2.00 g Klucel® EF (Hydroxypropylcellulose, Mw 80,000, Hercules Incorporated), and 15.00 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 600 ml Dimethylsulfoxide (DMSO). The solution was then spray dried at 210° C. The dry powder was then dispersed into distilled water, ethanol, and propylene glycol, respectively, and the nanoparticle size was measured with Malvern Nano-S. (SY-12)
- 0.25 g Divanillin, 0.25 g Klucel® EF (Hydroxypropylcellulose, Mw 80,000, Hercules Incorporated), and 4.50 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 100 ml Dimethylsulfoxide (DMSO). The solution was then spray dried at 210° C. The dry powder was then dispersed into distilled water, ethanol, and propylene glycol, respectively, and the nanoparticle size was measured with Malvern Nano-S. (SY-10)
- Details concerning these experiments and their results are summarized in Table 13.
-
TABLE 13 Actives, Klucel PVP, Solvent, Spray dry PS, nm Examples mg/ml EF, mg/ml mg/ml ml temp., ° C. H2O EtOH PPG 23 HED, 5.0 3.3 25.0 DMSO, 600 210 849 678 324 24 Divanillin, 2.5 45.0 DMSO, 100 210 627 520 396 2.5 Spray drying conditions: Aspiration rate: 100%; Pump rate: 1.80 ml/min. - 70% PVP (30K), 20% Pluronic F68 and 10% 1-naphthylamine dissolved in DCM (10% w/v).
- The solution was then spray dried at 50° C. with liquid feed rate at 3.02 ml/min. An off-white powder with 10 wt % (theoretical) 1-Naphthylamine was obtained.
- The powder was redispersible in water with a particle size Z average measuring 19.8 nm.
- 70% PVP (30K), 20% Pluronic F68 and 10% climbazole dissolved in Chloroform (2.5% w/v).
- The solution was then spray dried at 100° C. with liquid feed rate at 3.32 ml/min. A white powder with 10 wt % (theoretical) climbazole was obtained.
- The powder was redispersible in water with a particle size Z average measuring 166 nm.
- 400 mg λ-Cyhalothrin (20%), 360 mg Pluronic F68 (18%) and 1240 mg PVP-k30 (62%) were dissolved in 20 ml DCM to produce a pale brown translucent liquid.
- This solution was then spray dried at an inlet temperature of 160° C. and a pump rate of 3.6 ml/min.
- The resulting dry, white/pale brown powder was redispersed in water to produce a clear dispersion at a concentration of 1 mg/ml. The dispersions particle size was measured by DLS (see particle size trace below). Z-average (mass based size) was found to be 94.2 nm.
- 18 g of cocoPAS were dissolved in 240 ml water and then 185 ml of ethanol was added. 2 g of Tinopal™ SOP was dissolved in 240 ml dichloromethane and then 185 ml of ethanol was added to the resulting solution.
- The two solutions were combined and spray-dried using a Buchi mini B-290 with inlet temperature set at 125° C. and a 10% pump rate to give a pale yellow powder.
- On dispersion of 1 mg of the powder into 1 ml of water a nanoparticle size of 219 nm (Zave) was obtained.
- 0.6 g PVP (Mw 30K), 0.3 g Tween™ 40 and 0.1 g vitamin E were dissolved in 70 ml ethanol.
- The resulting solution was spray dried using a Buchi mini B-290 system. The Inlet temperature was set at 150° C. and the pump rate adjusted to approximately 3.6 ml/min.
- The product was recovered as a dry white powder which was redispersed in water to a concentration of 1 mg/ml and the particle size was measured using a Malvern Nano-S and found to be 17 nm (Zave)
- 0.6 g HPC, 0.3 g Tween™ 40 and 0.1 g vitamin E acetate were dissolved in 70 ml ethanol.
- The resulting solution was spray dried using a Buchi mini B-290 system. The Inlet temperature was set at 150° C. and the pump rate adjusted to approximately 3.6 ml/min.
- The product was recovered as a dry white powder which was redispersed in water to a concentration of 1 mg/ml and the particle size was measured using a Malvern Nano-S and found to be 94 nm (Zave)
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0613925.7A GB0613925D0 (en) | 2006-07-13 | 2006-07-13 | Improvements relating to nanodispersions |
GB0613925.7 | 2006-07-13 | ||
PCT/EP2007/056560 WO2008006712A2 (en) | 2006-07-13 | 2007-06-29 | Preparation of nanodispersions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090175953A1 true US20090175953A1 (en) | 2009-07-09 |
Family
ID=36955583
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/309,293 Abandoned US20090239749A1 (en) | 2006-07-13 | 2007-06-29 | Biocidal compositions |
US12/309,294 Active 2028-07-27 US8821932B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,292 Active 2030-01-29 US9060937B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,295 Abandoned US20100015233A1 (en) | 2006-07-13 | 2007-06-29 | anti-parasitic compositions |
US12/309,306 Abandoned US20090175953A1 (en) | 2006-07-13 | 2007-06-29 | Nanodispersions |
US12/309,343 Abandoned US20100008995A1 (en) | 2006-07-13 | 2007-07-13 | Processes for preparing pharmaceutical compositions |
US12/309,344 Expired - Fee Related US8945626B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical compositions |
US12/309,341 Expired - Fee Related US7691873B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical formulations |
US13/365,826 Abandoned US20120134940A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
US13/365,830 Abandoned US20120135058A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/309,293 Abandoned US20090239749A1 (en) | 2006-07-13 | 2007-06-29 | Biocidal compositions |
US12/309,294 Active 2028-07-27 US8821932B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,292 Active 2030-01-29 US9060937B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,295 Abandoned US20100015233A1 (en) | 2006-07-13 | 2007-06-29 | anti-parasitic compositions |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/309,343 Abandoned US20100008995A1 (en) | 2006-07-13 | 2007-07-13 | Processes for preparing pharmaceutical compositions |
US12/309,344 Expired - Fee Related US8945626B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical compositions |
US12/309,341 Expired - Fee Related US7691873B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical formulations |
US13/365,826 Abandoned US20120134940A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
US13/365,830 Abandoned US20120135058A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
Country Status (17)
Country | Link |
---|---|
US (10) | US20090239749A1 (en) |
EP (8) | EP2040677B1 (en) |
JP (9) | JP2009542764A (en) |
CN (11) | CN101489533A (en) |
AP (1) | AP2008004713A0 (en) |
AR (4) | AR061990A1 (en) |
AU (9) | AU2007271829B2 (en) |
BR (8) | BRPI0714176A2 (en) |
CA (8) | CA2656223A1 (en) |
CL (4) | CL2007002030A1 (en) |
ES (2) | ES2752460T3 (en) |
GB (1) | GB0613925D0 (en) |
IL (2) | IL195911A0 (en) |
MX (2) | MX2009000307A (en) |
TW (1) | TW200812694A (en) |
WO (8) | WO2008006716A2 (en) |
ZA (7) | ZA200900028B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080262100A1 (en) * | 2005-01-28 | 2008-10-23 | Andrew Ian Cooper | Method of Preparing Carrier Liquids |
WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
WO2012142160A1 (en) | 2011-04-12 | 2012-10-18 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
WO2015061361A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015134920A1 (en) | 2014-03-07 | 2015-09-11 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic crmp2 peptides targeting sodium channels for chronic pain |
WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
CN108601342A (en) * | 2016-02-02 | 2018-09-28 | 赢创德固赛有限公司 | Powdered formulation, its production method and its purposes with surface reactive material on solid, water soluble carrier |
WO2020186187A1 (en) | 2019-03-13 | 2020-09-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating bladder and urethra dysfunction and disease |
WO2021062012A1 (en) | 2019-09-25 | 2021-04-01 | Emory University | Use of klk10 and engineered derivatizations thereof |
WO2021146625A1 (en) | 2020-01-17 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene therapy for treatment of crx-autosomal dominant retinopathies |
WO2021225781A2 (en) | 2020-05-07 | 2021-11-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms |
WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
AR063704A1 (en) | 2006-09-14 | 2009-02-11 | Makhteshim Chem Works Ltd | PESTICIDE NANOPARTICLES OBTAINED OBTAINED FROM MICROEMULSIONS AND NANOEMULSIONS |
EP2813144A1 (en) | 2006-10-09 | 2014-12-17 | Charleston Laboratories, Inc. | Analgesic compositions comprising an antihistamine |
AR067047A1 (en) * | 2007-06-18 | 2009-09-30 | Combino Pharm Sl | ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. |
AR067048A1 (en) * | 2007-06-18 | 2009-09-30 | Combino Pharm Sl | ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. |
AU2008303129B2 (en) | 2007-09-25 | 2013-08-01 | Formulex Pharma Innovations Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
CA2749273C (en) | 2008-01-09 | 2018-09-04 | Charleston Laboratories, Inc. | Pharmaceutical oral dosage form comprising a triptan and an antiemetic |
TR200800634A2 (en) * | 2008-01-30 | 2009-02-23 | Takka Sevgi̇ | Fluvastatin tablet for extended release. |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
AU2009269473B2 (en) * | 2008-07-11 | 2012-02-16 | Nippon Soda Co., Ltd. | Method of manufacture of sustained-release formulation composition |
GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
AU2009295586B2 (en) | 2008-09-25 | 2014-01-09 | Vive Nano, Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
FR2938433B1 (en) * | 2008-11-19 | 2011-09-09 | Francois Fauran | PHARMACEUTICAL COMPOSITIONS USING INULIN AS A GRANULATING EXCIPIENT |
NZ593327A (en) * | 2008-12-12 | 2014-11-28 | Tim Tech Chemicals Ltd | Compositions for the treatment of timber and other wood substrates |
EP2243477A1 (en) * | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol for parenteral application |
NZ596610A (en) | 2009-05-27 | 2014-04-30 | Samyang Biopharmaceuticals | A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same |
HUP0900376A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate candesartan cilexetil composition |
HUP0900384A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
JP5442116B2 (en) * | 2009-06-25 | 2014-03-12 | ジン ヤン ファーム カンパニー リミテッド | Pharmaceutical composition containing losartan carboxylic acid and method for producing the same |
EP3311667A1 (en) | 2009-07-08 | 2018-04-25 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
CN102596252A (en) * | 2009-08-31 | 2012-07-18 | 蒂宝制药公司 | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
JP5498769B2 (en) * | 2009-12-04 | 2014-05-21 | 花王株式会社 | Method for producing lipid-soluble drug-encapsulating nanoparticles |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
SI2536396T1 (en) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
CN102802436A (en) | 2010-03-29 | 2012-11-28 | 弗门尼舍有限公司 | Spray-dried crystalline active ingredient |
GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
UA111167C2 (en) * | 2010-08-05 | 2016-04-11 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | PESTICIDIC COMPOSITIONS OF MECHANIZED PARTICLES WITH STRENGTH |
EP2624819A1 (en) | 2010-10-05 | 2013-08-14 | Iota NanoSolutions Limited | Processes for preparing improved compositions |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
JP2013001771A (en) * | 2011-06-14 | 2013-01-07 | Neos Co Ltd | Liquid mold control detergent composition |
RU2469536C1 (en) * | 2011-06-16 | 2012-12-20 | Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" | Fungicidal agent and method of its production |
EP2723452A2 (en) | 2011-06-22 | 2014-04-30 | Vyome Biosciences Pvt Ltd | Conjugate-based antifungal and antibacterial prodrugs |
JP6172718B2 (en) | 2011-08-23 | 2017-08-02 | ヴァイヴ クロップ プロテクション インコーポレイテッドVive Crop Protection Inc. | Pyrethroid formulation |
GB201115079D0 (en) | 2011-08-31 | 2011-10-19 | Iota Nanosolutions Ltd | Method of preparing carrier liquids |
GB201115635D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir and ritonavir |
GB201115634D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir |
GB201115633D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
US8609684B2 (en) | 2011-12-12 | 2013-12-17 | PruGen IP Holdings, Inc. | Solubilization and bioavailability of acetaminophen |
CA2882679C (en) | 2011-12-22 | 2019-10-15 | Vive Crop Protection Inc. | Strobilurin formulations |
EP2849770B1 (en) * | 2012-05-16 | 2020-07-29 | Mewa Singh | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
CA2877774C (en) | 2012-07-12 | 2017-07-18 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
US20140073678A1 (en) * | 2012-09-12 | 2014-03-13 | Monosol Rx, Llc | Anti-pain and anti-nausea and/or vomiting combinatorial compositions |
BR112015030501A2 (en) | 2013-06-04 | 2017-07-25 | Vyome Biosciences Pvt Ltd | coated particles and compositions comprising them |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
KR102017550B1 (en) * | 2013-11-13 | 2019-09-03 | 내셔널 디펜스 에듀케이션 앤드 리서치 파운데이션 | New acetaminophen compound composition without side effect to liver |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
EP2952208A1 (en) * | 2014-06-04 | 2015-12-09 | Universidade de Santiago de Compostela | Hydroalcoholic system for nail treatment |
ES2942619T3 (en) | 2014-06-11 | 2023-06-05 | SpecGx LLC | Spray-dried compositions with different dissolution profiles and procedures for their preparation |
CN104042626A (en) * | 2014-07-01 | 2014-09-17 | 李绍明 | Bactericidal and bacteriostatic agent |
DK3169315T3 (en) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Liquid-filled dosage form to prevent immediate release abuse |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
JP2018502742A (en) * | 2014-12-23 | 2018-02-01 | ダウ グローバル テクノロジーズ エルエルシー | Treated porous material |
JP6730315B2 (en) * | 2015-01-20 | 2020-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Solid dispersion of compounds using polyvinyl alcohol as carrier polymer |
CN104798772B (en) * | 2015-03-13 | 2017-05-24 | 中国农业科学院农业环境与可持续发展研究所 | Pesticide nano-solid dispersion and preparation method thereof |
JP2018524346A (en) | 2015-07-02 | 2018-08-30 | サイヴィタス セラピューティックス,インコーポレイテッド | Triptan powder for pulmonary delivery |
EP3324959B1 (en) * | 2015-07-17 | 2023-07-12 | The Board Of Regents Of The University Of Oklahoma | Licofelone derivatives and methods of use |
CN105145553A (en) * | 2015-10-12 | 2015-12-16 | 广西田园生化股份有限公司 | Indissolvable pesticide solid dispersion composition |
EP3423041A4 (en) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
BR112018076184A2 (en) * | 2016-06-16 | 2019-03-26 | The University Of Liverpool | solid composition, pharmaceutical or veterinary composition in injectable form, intramuscularly injectable formulation, subcutaneously injectable formulation, aqueous dispersion, oil dispersion, processes for preparing a solid composition, aqueous dispersion and oil dispersion, methods for treating and / or preventing a parasitic infection or fungal and to prevent malaria, and kit for preparing a sterile liquid formulation of atovaquone nanoparticles for injection. |
RU2619249C1 (en) * | 2016-11-07 | 2017-05-12 | Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) | Composition for seed treatment and method of its production |
US11498933B2 (en) | 2017-03-31 | 2022-11-15 | The John Hopkins University | Prodrug compositions |
TWI725314B (en) * | 2017-06-15 | 2021-04-21 | 松瑞製藥股份有限公司 | Methods for producing particles of an active ingredient |
EP3672411A4 (en) | 2017-08-25 | 2021-05-19 | Vive Crop Protection Inc. | Multi-component, soil-applied, pesticidal compositions |
US20190269662A1 (en) | 2018-03-02 | 2019-09-05 | The University Of Liverpool | Solid compositions of actives, processes for preparing same and uses of such solid compositions |
JP6858729B2 (en) * | 2018-05-25 | 2021-04-14 | ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation | New acetaminophen complex composition with no side effects on the liver |
WO2020135600A1 (en) * | 2018-12-28 | 2020-07-02 | 南京善思生物科技有限公司 | Nano pesticide formulation and preparation method therefor |
CN109846821B (en) * | 2019-01-03 | 2021-07-06 | 昆药集团股份有限公司 | Artemether nano preparation and preparation method thereof |
CN110074993A (en) * | 2019-06-05 | 2019-08-02 | 山东大学 | A method of preparing ultraviolet absorber nano particle |
AU2020302856A1 (en) * | 2019-06-28 | 2022-02-17 | Solstar Pharma | Extended release gastroretentive formulation against Helicobacter Pylori |
KR20220090524A (en) * | 2019-10-28 | 2022-06-29 | 구미아이 가가쿠 고교 가부시키가이샤 | Agrochemical composition and its manufacturing method |
IT202000022789A1 (en) | 2020-09-28 | 2020-12-28 | Vitop Moulding Srl | Dispenser tap equipped with positioning, blocking and orientation system on Bag-In-Box type boxes |
GB202115049D0 (en) | 2021-10-20 | 2021-12-01 | Univ Liverpool | Chemical Compositions |
CN114732009B (en) * | 2022-06-13 | 2022-08-23 | 山东百农思达生物科技有限公司 | Preparation method of water dispersible granules containing pyraclostrobin and dimethomorph |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4081529A (en) * | 1976-05-05 | 1978-03-28 | Inverni Della Beffa S.P.A. | Polyhydroxyphenylchromanones |
US5985248A (en) * | 1996-12-31 | 1999-11-16 | Inhale Therapeutic Systems | Processes for spray drying solutions of hydrophobic drugs and compositions thereof |
US20020041896A1 (en) * | 1999-05-27 | 2002-04-11 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US20030198674A1 (en) * | 2002-02-01 | 2003-10-23 | Curatolo William J. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
US20040028505A1 (en) * | 2002-06-07 | 2004-02-12 | Bilbrey Robert A. | Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms |
US20040064834A1 (en) * | 2001-08-21 | 2004-04-01 | Masayuki Kuwata | Information processing system, information processing apparatus and method |
US20040194338A1 (en) * | 2002-02-01 | 2004-10-07 | Pfizer Inc | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
US20040202669A1 (en) * | 2002-12-27 | 2004-10-14 | O'hagan Derek | Immunogenic compositions containing phospholipid |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US6835396B2 (en) * | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US20050014043A1 (en) * | 2003-07-18 | 2005-01-20 | Matsushita Electric Industrial Co., Ltd. | Power supply unit |
US20050163855A1 (en) * | 2004-01-27 | 2005-07-28 | Cj Corporation | Method of preparing low-crystallinity oltipraz or amorphous oltipraz |
US20060003011A1 (en) * | 2001-06-22 | 2006-01-05 | Pfizer Inc | Pharmaceutical compositions of drugs and neutralized acidic polymers |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB501835A (en) | 1936-05-29 | 1939-03-02 | Siemens Ag | Process and apparatus for reducing the power required for the mechanical treatment of movable masses |
GB1305024A (en) * | 1969-07-10 | 1973-01-31 | ||
US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
DE3439482A1 (en) | 1984-10-27 | 1986-05-07 | Röhm GmbH, 6100 Darmstadt | METHOD FOR COATING SUBSTRATES WITH SCRATCH-RESISTANT, NON-REFLECTIVE COVERS |
US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US5160530A (en) * | 1989-01-24 | 1992-11-03 | Griffin Corporation | Microencapsulated polymorphic agriculturally active material |
GB8918807D0 (en) * | 1989-08-17 | 1989-09-27 | Shell Int Research | A solid pesticidal formulation,a process for its preparation and the use thereof |
JP3067810B2 (en) * | 1990-12-21 | 2000-07-24 | 中外製薬株式会社 | Method for producing dry powder of O / W emulsion for oral administration |
GB9304294D0 (en) * | 1993-03-03 | 1993-04-21 | Zeneca Ltd | Herbicidal compositions |
DE4329446A1 (en) * | 1993-09-01 | 1995-03-02 | Basf Ag | Process for the production of finely divided color or active substance preparations |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
TW318777B (en) * | 1995-06-29 | 1997-11-01 | Novartis Ag | |
EP0862420A4 (en) * | 1995-10-13 | 1999-11-03 | Penn State Res Found | Synthesis of drug nanoparticles by spray drying |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
US5858409A (en) | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
JP4183279B2 (en) * | 1997-04-15 | 2008-11-19 | アール ピー シェーラー テクノロジーズ インコーポレーテッド | Hydrolyzed cellulose granules for pharmaceutical use |
WO1999044594A1 (en) * | 1998-03-05 | 1999-09-10 | Nippon Shinyaku Co., Ltd. | Fat emulsions for inhalational administration |
JPH11322587A (en) | 1998-05-18 | 1999-11-24 | Sumitomo Chem Co Ltd | Microcapsulation of physiologically active substance solid at room temperature and microcapsule composition obtained thereby |
JP2002534371A (en) * | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | Method for producing pharmaceutically active ingredient containing water-insoluble drug and pharmaceutical composition for oral administration containing the same |
ATE400252T1 (en) * | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | PHARMACEUTICAL SOLID DISPERSIONS |
GB9904012D0 (en) | 1999-02-22 | 1999-04-14 | Zeneca Ltd | Agrochemical formulation |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
ES2250141T5 (en) | 1999-05-27 | 2009-11-05 | Acusphere, Inc. | POROUS MATRICES OF DRUGS AND METHODS TO MANUFACTURE THEM. |
GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
GB9920148D0 (en) * | 1999-08-25 | 1999-10-27 | Smithkline Beecham Plc | Novel composition |
ATE311227T1 (en) | 1999-12-01 | 2005-12-15 | Natco Pharma Ltd | FAST-ACTING, FREEZE-DRIED, ORAL, PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF MIGRAINE |
KR100694667B1 (en) * | 1999-12-08 | 2007-03-14 | 동아제약주식회사 | Antifungal compositions containing itraconazole with both improved bioavailability and narrow intra- and inter-individual variation of its absorption |
US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
WO2001089484A2 (en) * | 2000-05-22 | 2001-11-29 | Verion, Inc. | Method for increasing the compressibility of poorly binding powder materials |
US6932963B2 (en) * | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
IT1318618B1 (en) * | 2000-07-10 | 2003-08-27 | A C R Applied Coating Res S A | QUICK RELEASE BIOADHESIVE MICROSPHERES FOR SUBLINGUAL ADMINISTRATION OF ACTIVE INGREDIENTS. |
WO2002007724A1 (en) * | 2000-07-24 | 2002-01-31 | Ono Pharmaceutical Co., Ltd. | FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME |
DE10036871A1 (en) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersions for the formulation of poorly or poorly soluble active ingredients |
ATE367802T1 (en) * | 2000-09-20 | 2007-08-15 | Jagotec Ag | METHOD FOR SPRAY DRYING COMPOSITIONS CONTAINING FENOFIBRATE |
US6756062B2 (en) * | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
WO2002060411A2 (en) * | 2001-01-30 | 2002-08-08 | Board Of Regents University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
US6355675B1 (en) | 2001-05-15 | 2002-03-12 | Isp Investments Inc. | Emulsifiable concentrate of a water-insoluble fungicide |
MXPA03011017A (en) * | 2001-06-01 | 2005-04-29 | Pozen Inc | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs. |
KR100425226B1 (en) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | Compositions and preparation methods for bioavailable oral aceclofenac dosage forms |
MXPA04002446A (en) * | 2001-09-26 | 2004-07-23 | Baxter Int | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal. |
DE10151392A1 (en) * | 2001-10-18 | 2003-05-08 | Bayer Cropscience Ag | Powdery solid formulations |
JP4235109B2 (en) * | 2001-11-07 | 2009-03-11 | ビーエーエスエフ ソシエタス・ヨーロピア | Crop protection solid formulation containing sinidone-ethyl and corresponding dispersion |
US20040266626A1 (en) * | 2001-11-07 | 2004-12-30 | Wolfgang Schrof | Solid crop protection formulations and dispersion formulations and their use in agriculture |
US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
EP1531799A1 (en) | 2002-06-10 | 2005-05-25 | Elan Pharma International Limited | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
DE10244681A1 (en) | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | New solid telmisartan-containing pharmaceutical formulations and their preparation |
CA2500908A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
CN1176649C (en) * | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | Inhalant of Shumaputan dry-powder and its preparation method |
AU2003304108B2 (en) * | 2002-10-30 | 2007-03-22 | Spherics, Inc. | Nanoparticulate bioactive agents |
PT1575566E (en) * | 2002-12-26 | 2012-03-29 | Pozen Inc | Multilayer dosage forms containing naproxen and triptans |
US20060210620A1 (en) * | 2003-01-21 | 2006-09-21 | Kumra Pannanchukunnath M | Co-precipitated amorphous losartan and dosage forms comprising the same |
US20040197301A1 (en) * | 2003-02-18 | 2004-10-07 | Zhong Zhao | Hybrid polymers and methods of making the same |
AU2004212976A1 (en) * | 2003-02-19 | 2004-09-02 | Biovail Laboratories Inc. | Rapid absorption selective 5-HT agonist formulations |
WO2004075921A1 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
JP2006522819A (en) | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | Combination therapy of constipation combined with laxatives and peripheral opioid antagonists |
CA2465565A1 (en) | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
JP2009513543A (en) * | 2003-07-16 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Chlorthalidone combination |
CL2004001884A1 (en) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS. |
DE10338403A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant |
DE10351004A1 (en) * | 2003-10-30 | 2005-05-25 | Basf Ag | Aqueous nanodispersion-forming formulations of active agents, especially plant protectants such as fungicides, comprise random copolymer of unsaturated sulfonic acid(s) |
DE10351087A1 (en) | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Solid active ingredient formulation |
KR100603974B1 (en) * | 2003-12-05 | 2006-07-25 | 김갑식 | Method for preparing nano-scale or amorphous particle using solid fat as a solvent |
BRPI0418294A (en) * | 2003-12-31 | 2007-05-02 | Pfizer Prod Inc | stabilized solid pharmaceutical compositions of low solubility drugs, poloxamers and stabilizing polymers |
IL160095A0 (en) * | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
JP2005298347A (en) * | 2004-04-06 | 2005-10-27 | Yoshiaki Kawashima | Inhalation preparation and method for producing the same |
KR100598326B1 (en) | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | EXTENDED RELEASE ORAL FORMULATION OF HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF |
RU2006141846A (en) | 2004-04-28 | 2008-06-10 | Юнилевер Н.В. (Nl) | FAT OIL CONTAINING STATINS |
WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
CA2560984A1 (en) | 2004-06-01 | 2005-12-15 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Process for preparation of amorphous form of a drug |
DE102004031298A1 (en) | 2004-06-28 | 2006-01-12 | Basf Ag | Aqueous dispersions of poorly water-soluble or water-insoluble active ingredients and dry powders prepared therefrom containing at least one polymer containing polyether groups as protective colloid |
WO2006038552A1 (en) * | 2004-10-01 | 2006-04-13 | Eisai R & D Management Co., Ltd. | Composition containing fine particles and process for producing the same |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
CA2594332A1 (en) * | 2005-01-06 | 2006-07-13 | Elan Pharma International Ltd. | Nanoparticulate candesartan formulations |
GB0501835D0 (en) * | 2005-01-28 | 2005-03-09 | Unilever Plc | Improvements relating to spray dried compositions |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
WO2008076780A2 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments Inc. | Amorphous valsartan and the production thereof |
-
2006
- 2006-07-13 GB GBGB0613925.7A patent/GB0613925D0/en not_active Ceased
-
2007
- 2007-06-29 ES ES07786932T patent/ES2752460T3/en active Active
- 2007-06-29 EP EP07765733.6A patent/EP2040677B1/en active Active
- 2007-06-29 EP EP07765734A patent/EP2040678A2/en not_active Withdrawn
- 2007-06-29 CA CA002656223A patent/CA2656223A1/en not_active Abandoned
- 2007-06-29 JP JP2009518835A patent/JP2009542764A/en active Pending
- 2007-06-29 ZA ZA200900028A patent/ZA200900028B/en unknown
- 2007-06-29 MX MX2009000307A patent/MX2009000307A/en not_active Application Discontinuation
- 2007-06-29 US US12/309,293 patent/US20090239749A1/en not_active Abandoned
- 2007-06-29 AU AU2007271829A patent/AU2007271829B2/en not_active Ceased
- 2007-06-29 ES ES07765733T patent/ES2741124T3/en active Active
- 2007-06-29 AU AU2007271827A patent/AU2007271827B2/en not_active Ceased
- 2007-06-29 BR BRPI0714176-9A patent/BRPI0714176A2/en not_active IP Right Cessation
- 2007-06-29 AU AU2007271830A patent/AU2007271830B2/en not_active Ceased
- 2007-06-29 ZA ZA200900031A patent/ZA200900031B/en unknown
- 2007-06-29 CA CA002656233A patent/CA2656233A1/en not_active Abandoned
- 2007-06-29 WO PCT/EP2007/056564 patent/WO2008006716A2/en active Search and Examination
- 2007-06-29 JP JP2009518834A patent/JP2009542763A/en active Pending
- 2007-06-29 CA CA002656217A patent/CA2656217A1/en not_active Abandoned
- 2007-06-29 CN CNA2007800262750A patent/CN101489533A/en active Pending
- 2007-06-29 ZA ZA200900029A patent/ZA200900029B/en unknown
- 2007-06-29 CN CN201010193750A patent/CN101849911A/en active Pending
- 2007-06-29 BR BRPI0714177-7A patent/BRPI0714177A2/en not_active IP Right Cessation
- 2007-06-29 WO PCT/EP2007/056561 patent/WO2008006713A2/en active Application Filing
- 2007-06-29 WO PCT/EP2007/056560 patent/WO2008006712A2/en active Search and Examination
- 2007-06-29 CN CNA2007800262267A patent/CN101489531A/en active Pending
- 2007-06-29 CN CN2012101088434A patent/CN102631874A/en active Pending
- 2007-06-29 EP EP07786931A patent/EP2040679A2/en not_active Ceased
- 2007-06-29 AU AU2007271831A patent/AU2007271831B2/en not_active Ceased
- 2007-06-29 JP JP2009518832A patent/JP2009542761A/en active Pending
- 2007-06-29 US US12/309,294 patent/US8821932B2/en active Active
- 2007-06-29 EP EP11005052A patent/EP2386292A1/en active Pending
- 2007-06-29 WO PCT/EP2007/056563 patent/WO2008006715A2/en active Application Filing
- 2007-06-29 CN CNA2007800263575A patent/CN101489534A/en active Pending
- 2007-06-29 WO PCT/EP2007/056562 patent/WO2008006714A2/en active Application Filing
- 2007-06-29 EP EP20100175541 patent/EP2269581A1/en not_active Withdrawn
- 2007-06-29 CN CNA2007800262657A patent/CN101489532A/en active Pending
- 2007-06-29 CA CA2656229A patent/CA2656229C/en active Active
- 2007-06-29 EP EP07786933.7A patent/EP2040681B1/en active Active
- 2007-06-29 JP JP2009518831A patent/JP2009542760A/en active Pending
- 2007-06-29 BR BRPI0722376-5A patent/BRPI0722376A2/en not_active IP Right Cessation
- 2007-06-29 ZA ZA200900027A patent/ZA200900027B/en unknown
- 2007-06-29 MX MX2009000309A patent/MX2009000309A/en not_active Application Discontinuation
- 2007-06-29 BR BRPI0714230-7A patent/BRPI0714230A2/en not_active IP Right Cessation
- 2007-06-29 CA CA002659666A patent/CA2659666A1/en not_active Abandoned
- 2007-06-29 BR BRPI0714179-3A patent/BRPI0714179A2/en not_active IP Right Cessation
- 2007-06-29 JP JP2009518833A patent/JP2009542762A/en active Pending
- 2007-06-29 US US12/309,292 patent/US9060937B2/en active Active
- 2007-06-29 US US12/309,295 patent/US20100015233A1/en not_active Abandoned
- 2007-06-29 ZA ZA200900030A patent/ZA200900030B/en unknown
- 2007-06-29 AU AU2007271828A patent/AU2007271828B2/en not_active Ceased
- 2007-06-29 AP AP2008004713A patent/AP2008004713A0/en unknown
- 2007-06-29 US US12/309,306 patent/US20090175953A1/en not_active Abandoned
- 2007-06-29 CN CN2012101088167A patent/CN102671585A/en active Pending
- 2007-06-29 EP EP07786932.9A patent/EP2040680B1/en active Active
- 2007-06-29 EP EP11005053A patent/EP2387992A1/en not_active Ceased
- 2007-06-29 CN CNA2007800263679A patent/CN101489535A/en active Pending
- 2007-07-11 TW TW096125298A patent/TW200812694A/en unknown
- 2007-07-12 CL CL2007002030A patent/CL2007002030A1/en unknown
- 2007-07-12 CL CL2007002031A patent/CL2007002031A1/en unknown
- 2007-07-12 CL CL2007002032A patent/CL2007002032A1/en unknown
- 2007-07-13 CN CNA2007800338942A patent/CN101516342A/en active Pending
- 2007-07-13 BR BRPI0714353-2A patent/BRPI0714353A2/en not_active Application Discontinuation
- 2007-07-13 BR BRPI0714352-4A patent/BRPI0714352A2/en not_active IP Right Cessation
- 2007-07-13 AU AU2007274039A patent/AU2007274039A1/en not_active Abandoned
- 2007-07-13 CN CNA2007800338285A patent/CN101516340A/en active Pending
- 2007-07-13 US US12/309,343 patent/US20100008995A1/en not_active Abandoned
- 2007-07-13 JP JP2009518979A patent/JP2009542794A/en active Pending
- 2007-07-13 JP JP2009518978A patent/JP2009542793A/en active Pending
- 2007-07-13 CN CNA2007800338444A patent/CN101516341A/en active Pending
- 2007-07-13 AR ARP070103116A patent/AR061990A1/en not_active Application Discontinuation
- 2007-07-13 AU AU2007274040A patent/AU2007274040A1/en not_active Abandoned
- 2007-07-13 WO PCT/GB2007/050408 patent/WO2008007151A2/en active Application Filing
- 2007-07-13 AR ARP070103118A patent/AR061992A1/en not_active Application Discontinuation
- 2007-07-13 CA CA002657586A patent/CA2657586A1/en not_active Abandoned
- 2007-07-13 CA CA002657582A patent/CA2657582A1/en not_active Abandoned
- 2007-07-13 JP JP2009518980A patent/JP2009542795A/en active Pending
- 2007-07-13 ZA ZA200900347A patent/ZA200900347B/en unknown
- 2007-07-13 WO PCT/GB2007/050407 patent/WO2008007150A1/en active Application Filing
- 2007-07-13 US US12/309,344 patent/US8945626B2/en not_active Expired - Fee Related
- 2007-07-13 CA CA002657548A patent/CA2657548A1/en not_active Abandoned
- 2007-07-13 ZA ZA200900345A patent/ZA200900345B/en unknown
- 2007-07-13 BR BRPI0714351-6A patent/BRPI0714351A2/en not_active IP Right Cessation
- 2007-07-13 WO PCT/GB2007/050409 patent/WO2008007152A2/en active Application Filing
- 2007-07-13 AR ARP070103117A patent/AR061991A1/en not_active Application Discontinuation
- 2007-07-13 US US12/309,341 patent/US7691873B2/en not_active Expired - Fee Related
- 2007-07-13 AU AU2007274041A patent/AU2007274041A1/en not_active Abandoned
-
2008
- 2008-12-11 IL IL195911A patent/IL195911A0/en unknown
- 2008-12-15 IL IL195933A patent/IL195933A/en not_active IP Right Cessation
-
2010
- 2010-05-11 AU AU2010201900A patent/AU2010201900A1/en not_active Abandoned
- 2010-05-19 CL CL2010000516A patent/CL2010000516A1/en unknown
- 2010-06-08 JP JP2010131047A patent/JP2010202665A/en not_active Withdrawn
- 2010-06-23 AR ARP100102205A patent/AR077195A2/en not_active Application Discontinuation
-
2012
- 2012-02-03 US US13/365,826 patent/US20120134940A1/en not_active Abandoned
- 2012-02-03 US US13/365,830 patent/US20120135058A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4081529A (en) * | 1976-05-05 | 1978-03-28 | Inverni Della Beffa S.P.A. | Polyhydroxyphenylchromanones |
US5985248A (en) * | 1996-12-31 | 1999-11-16 | Inhale Therapeutic Systems | Processes for spray drying solutions of hydrophobic drugs and compositions thereof |
US20020041896A1 (en) * | 1999-05-27 | 2002-04-11 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US20060003011A1 (en) * | 2001-06-22 | 2006-01-05 | Pfizer Inc | Pharmaceutical compositions of drugs and neutralized acidic polymers |
US20040064834A1 (en) * | 2001-08-21 | 2004-04-01 | Masayuki Kuwata | Information processing system, information processing apparatus and method |
US6835396B2 (en) * | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US20030198674A1 (en) * | 2002-02-01 | 2003-10-23 | Curatolo William J. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
US20040194338A1 (en) * | 2002-02-01 | 2004-10-07 | Pfizer Inc | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
US20040028505A1 (en) * | 2002-06-07 | 2004-02-12 | Bilbrey Robert A. | Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms |
US20040202669A1 (en) * | 2002-12-27 | 2004-10-14 | O'hagan Derek | Immunogenic compositions containing phospholipid |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US20050014043A1 (en) * | 2003-07-18 | 2005-01-20 | Matsushita Electric Industrial Co., Ltd. | Power supply unit |
US20050163855A1 (en) * | 2004-01-27 | 2005-07-28 | Cj Corporation | Method of preparing low-crystallinity oltipraz or amorphous oltipraz |
Non-Patent Citations (1)
Title |
---|
SX Yin, M Franchini, J Chen, A Hsieh, S Jen, T Lee, M Hussain, R Smith. "Bioavailability Enhancement of a COX-2 Inhibitor, BMS-347070, from a Nanocrystalline Dispersion Prepared by Spray-Drying." Journal of Pharmaceutical Sciences, Vol. 94, No. 7, July 2005, pages 1598-1607. * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080262100A1 (en) * | 2005-01-28 | 2008-10-23 | Andrew Ian Cooper | Method of Preparing Carrier Liquids |
WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
WO2012142160A1 (en) | 2011-04-12 | 2012-10-18 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
WO2015061361A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015134920A1 (en) | 2014-03-07 | 2015-09-11 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic crmp2 peptides targeting sodium channels for chronic pain |
CN108601342A (en) * | 2016-02-02 | 2018-09-28 | 赢创德固赛有限公司 | Powdered formulation, its production method and its purposes with surface reactive material on solid, water soluble carrier |
US20190037838A1 (en) * | 2016-02-02 | 2019-02-07 | Evonik Degussa Gmbh | Powdery formulations with surface active substances on solid, water-soluble carriers, method for the production and use thereof |
WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
WO2020186187A1 (en) | 2019-03-13 | 2020-09-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating bladder and urethra dysfunction and disease |
WO2021062012A1 (en) | 2019-09-25 | 2021-04-01 | Emory University | Use of klk10 and engineered derivatizations thereof |
WO2021146625A1 (en) | 2020-01-17 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene therapy for treatment of crx-autosomal dominant retinopathies |
WO2021225781A2 (en) | 2020-05-07 | 2021-11-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms |
WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090175953A1 (en) | Nanodispersions | |
CA2601340C (en) | Improvements relating to rapidly dissolving compositions | |
US20170112125A1 (en) | Processes for preparing improved compositions | |
US20110217381A1 (en) | Pharmaceutical compositions | |
US9718036B2 (en) | Method of preparing carrier liquids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CONOPCO, INC. D/B/A UNILEVER, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANGUS, DORIS;DUNCALF, DAVID JOHN;ELPHICK, ANDREW JAMES;AND OTHERS;REEL/FRAME:022518/0499 Effective date: 20070726 |
|
AS | Assignment |
Owner name: IOTA NANOSOLUTIONS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOPCO, INC. D/B/A UNILEVER;REEL/FRAME:025886/0872 Effective date: 20110225 |
|
AS | Assignment |
Owner name: IOTA NANOSOLUTIONS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOPCO, INC. D/B/A UNILEVER;REEL/FRAME:026485/0862 Effective date: 20110610 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |